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Depressive symptoms are experienced by 13-20% of the world population at any 
given point in time and guidelines for diagnosis can be found in the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV), published by the 
American Psychiatric Association. Treatments for depression include antidepressants, 
electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS) and 
omega-3 supplementation. Many antidepressants are able to interact with the lipid bilayer 
(Seydel et al., 1994, Fisar et al., 2004) and studies show a correlation between the intake 
of omega-3 supplements and the prevalence of depression (Hibbeln, 1998, De Vriese et 
al., 2004, Astorg et al., 2008). 
The link between antidepressants and lipid in depression is the basis of this study. 
Lipids are essential in maintaining homeostasis of the cellular environment but it is still 
vague with regards to how antidepressants affect lipid profiles. Therefore, changes in 
lipid profiles in various regions of the mouse brain after antidepressant therapy using 
lipidomics was examined. Results showed a drop in phospholipids with a corresponding 
increase in lysophospholipids in the region of the prefrontal cortex (PFC), evidencing the 
presence of enhanced phospholipase A2 (PLA2) enzyme activity with resultant 
endogenous release of fatty acids such as docosahexaenoic acid (DHA) (Lee et al., 2009). 
In brain tissues, the basal expression and activity of calcium-independent PLA2 (iPLA2) 
is higher than either cytosolic PLA2 (cPLA2) or secretory PLA2 (sPLA2). In addition, 





phospholipids (Strokin et al., 2003, Rao et al., 2007a), it was hypothesized that enhanced 
iPLA2 activity might be responsible for the antidepressant effect. 
Hence, the subsequent portion of the study used an antisense oligonucleotide to 
iPLA2, along with forced swim test (FST) and lipidomics to investigate the role of iPLA2. 
It was found that iPLA2 was essential in the reduction of stress-related behavioral despair 
brought about by the antidepressant, maprotiline. Lipidomic analyses showed that 
antisense treatment was able to reverse lipid changes brought about by maprotiline. The 
direct association of abolition of antidepressant activity of maprotiline with iPLA2 
inhibition, and the lack of release of long chain fatty acids, including DHA, demonstrated 
a role for iPLA2 in the antidepressant effect of maprotiline, and possibly other 
antidepressants which show similar release of long chain fatty acids in the PFC after 
chronic treatment in mice.  
Finally, the last part of the study used rTMS, which has been shown to be 
effective in the management of depression (Avery et al., 2008, Bloch et al., 2008, 
Fitzgerald, 2008, George et al., 2010). We proposed that perhaps similar trends in lipid 
changes indicating PLA2 activity would be observed after rTMS, thereby supporting the 
evidence for a common downstream effect amongst various treatment modalities of 
depression, including omega-3 supplementation. Indeed, there were significant alterations 
in phospholipid species with long chain polyunsaturated fatty acids (PUFAs). They 
showed decreases in abundance together with corresponding increases in 
lysophospholipid species, signifying endogenous release of long chain fatty acids 
primarily in the PFC, perhaps involving PLA2 isoforms as well. 
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Chapter I Introduction 




1.1. General introduction to depression 
1.1.1. Epidemiology of depression 
Depression is an emotion that is universally experienced by virtually everyone at 
some point of time in life. Epidemiological studies have consistently shown that major 
depressive disorder (MDD) is one of the most prevalent lifetime psychiatric disorders 
(Fava and Kendler, 2000). About 13-20% of the world population has some depressive 
symptoms at any given time and about 5% of the population is estimated to suffer from 
major depression (Licinio and Wong, 1999).  A meta-analyses concluded that genetic 
influences were the most important contributor in familiar aggregation of depression, 
with heritability of liability to MDD of 31-42% (Sullivan et al., 2000). However, 
vulnerability to depression is only partly genetic, with environmental factors playing a 
greater role when it comes to non-related individuals (Sullivan et al., 2000). Nongenetic 
factors as diverse as stress and emotional trauma, adverse childhood experience, viral 
infections (e.g. Borna virus) have been implicated in the etiology of depression (Fava and 
Kendler, 2000). Across many studies, women have been shown to be at consistently 
greater risk for MDD than men (Wilhelm et al., 1997, Hankin and Abramson, 1999), with 
the ratio of prevalence rates in women to men occurring in the range of 1.5 to 2.5 (Fava 
and Kendler, 2000).  
Current diagnostic criteria for MDD can be found in the American Psychiatric 
Association's DSM-IV manual. According to DSM-IV manual, a diagnosis of MDD is 
made when at least 5 of the symptoms listed below are reported for longer than a 2 week 
period of time, and when the symptoms disrupt normal social and occupational 
functioning. At least one of the symptoms is either (1) depressed mood or (2) loss of 




interest or pleasure. The list of symptoms include (1) depressed mood; (2) loss of interest, 
markedly diminished interest or pleasure in all, or almost all activities most of the day, 
nearly everyday; (3) significant weight loss / weight gain; (4) insomnia / hypersomnia 
nearly everyday; (5) psychomotor agitgation / retardation nearly everyday;  (6) fatigue or 
loss of energy nearly everyday; (7) feelings of worthlessness or excessive or 
inappropriate guilt nearly everyday; (8) Diminished ability to think or concentrate, or 
indecisiveness, nearly every day; (9) Recurrent thoughts of death, recurrent suicidal 
ideation without a specific plan, or a suicide attempt or specific plan for committing 
suicide. The official diagnosis of depression is subjective and rests on the documentation 
of a certain number of symptoms that significantly impair functioning for specific 
duration. 
 Current treatments for depression are inadequate for many individuals, and 
progress in understanding the neurobiology of depression is slow. Observing pathological 
changes in the brain as a result of depression is more difficult than for all other organs. In 
addition, by the time depression is being diagnosed, the pathological changes would have 
already taken place or become confounded with other co-morbidities, making the 
understanding of its etiology difficult. Treatment of depression itself is also filled with 
difficulties. As many as 30-40% of patients do not respond to treatment (Kornstein and 
Schneider, 2001, Stahl, 2008). Moreover, the 20-30% of patients who do respond to 
antidepressant treatments will fail to maintain their treatment response (Stahl, 2008). 
These statistics fuel the relentless search for improvements in current pharmacotherapy as 
well as the discovery of new treatment regimens.  
   




1.1.2. Etiology of depression 
1.1.2.1. Monoamine hypothesis of depression 
The principal monoamine neurotransmitters in the brain are the catecholamines 
norepinephrine (NE) and dopamine (DA), and the indoleamine, serotonin (5-HT). NE is 
produced from tyrosine precursors inside the NE neuron and stored in vesicles until it is 
released by a nerve impulse. Breakdown of NE to inactive metabolites occurs via 
monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) enzymes. The 
action of NE in the synaptic cleft can be terminated by the enzymes mentioned above or a 
transport pump for NE, the NE transporter / NE reuptake pump (NET) located on the 
presynaptic terminal. Synthesis of 5-HT takes place via the precursor, tryptophan, in 5-
HT neurons. Likewise to NE, the breakdown of 5-HT into inactive metabolites takes 
place via MAO enzyme. Also, the presynaptic terminal of the 5-HT neuron has a 
transport pump for 5-HT called the 5-HT transporter / 5-HT reuptake pump (SERT), 
analogous to the NE transporter in NE neurons. Arising from early observations, the 
monoamine hypothesis of depression posits that depression is caused by a lack of 
monoamine function in the brain (Delgado, 2004, Krishnan and Nestler, 2008). Hence, 
most antidepressants work by increasing the availability of NE / 5-HT via inhibiting their 
reuptake by the NET / SERT. 
Studies looking at levels of NE/ 5-HT have proven that the monoamine 
hypothesis might not be absolutely accurate. For example, there is a large number of 
depressed patients who do not respond to on-going antidepressant treatments which serve 
to increase monoamine levels in the brain (Nestler et al., 2002). Much early research was 
to identify the predicted deficiencies of the monoamine neurotransmitters. However, such 




deficiencies have not been uniformly observed. Some studies showed that 5-HT reduction 
through tryptophan (a precursor for 5-HT) depletion can result in depression (Smith et al., 
1987, Benkelfat et al., 1994, Ellenbogen et al., 1996). On the contrary, other depletion 
studies did not show worsening of symptoms of depressed patients or cause depression in 
healthy volunteers (Miller et al., 1992, Delgado et al., 1994, Neumeister et al., 1997). It 
was believed that low levels of a 5-HT metabolite, 5-hydroxyindoleacetic-acid (5-HIAA) 
in the cerebrospinal fluid (CSF) of patients were able to predict for depression since low 
5-HIAA would reflect low 5-HT levels (Stanley et al., 1985, Placidi et al., 2001). Furthur 
investigation supported this by showing that depressed patients who had low 5-HIAA had 
a significantly higher incidence of suicide attempts than patients with high 5-HIAA levels 
(Asberg et al., 1976).  In fact, the difference in 5-HIAA levels may be related to the 
degree of violence involved in suicidal victims. Patients who used more violents means 
of suicide had significantly lower CSF 5-HIAA levels than the suicide patients who used 
less violent means, therefore, implying that low CSF 5-HIAA might be a marker for 
impulsivity, more so than depression (Asberg et al., 1976). Subsequently, it was also 
reported that CSF 5-HIAA levels were reduced in populations who had personality 
disorders and social impulsivity, some of them guilty of homicide, but none were 
depressed (Brown et al., 1979, Brown and Linnoila, 1990, Lidberg et al., 2000, Fairbanks 
et al., 2001). Thus, low CSF 5-HIAA, and therefore 5-HT dysfunctions may be linked 
with impulse control problems other than depression. 
 Studies of tissue from the locus coeruleus (LC) region of suicide victims have 
shown an increased density and sensitivity of α2-adrenergic receptors compared with 
controls (Ordway et al., 2003). The α2-adrenergic receptor, which is usually presynaptic, 




modulates NE release via feedback inhibition (Belmaker and Agam, 2008, Stahl, 2008). 
This result lends support to the fact that an inherent NE deficiency causes secondary 
changes in the density and responsiveness of the α2-adrenergic receptors. Tyroxine 
hydroxylase, which is required for the synthesis of NE, is found to have elevated 
expression in the LC in major depression as shown by immunostaining (Zhu et al., 1999). 
This is said to come about as a result of compensatory overactivity of the NE neurons due 
to a lack of NE (Zhu et al., 1999). 
A post-mortem study on neuronal morphology in all subnuclei of the dorsal raphe 
nuclei (DRN) using nissl stained sections of the brainstem showed that patients with 
mood disorders have a deficient number of neurons in the DRN (Baumann et al., 2002). 
This structural deviation may contribute to impaired 5-HT innervation of brain regions 
which are involved in the pathology of mood disorders. In post-mortem studies of suicide 
victims and depressed patients, MDD is accompanied by down-regulated or desensitized 
presynpatic and postsynaptic 5-HT1A receptors (Lesch et al., 1990, Drevets et al., 1999, 
Riedel et al., 2002, Meltzer et al., 2004). A study evaluating the 5-HT1A receptor by 
injecting specific agonists and measuring neuroendocrine responses suggested that the 
sensitivity of this 5-HT1A receptor was reduced in patients with depression (Pitchot et al., 
2005).  
Contrary to above data, enhanced binding of [3H]8-hydroxy-2-(di-n-
propyl)aminotetralin, an agonist at 5-HT1A receptors, was increased significantly in the 
DRN of suicide victims with major depression (Stockmeier et al., 1998). Increased 
binding of 5-HT1A, which is an inhibitory autoreceptor, will in turn cause diminished 
activity of 5-HT neurons, resulting in depression (Stockmeier et al., 1998). 




Antidepressant treatments desensitize the 5-HT1A autoreceptor, which may be an 
important mechanism by which 5-HT neurotransmission is being enhanced (Stahl, 1994, 
Giovacchini et al., 2005). The evidence for reduced 5-HT1A receptor sensitivity in the 
DRN in positron emission tomography studies as mentioned above (Drevets et al., 1999, 
Meltzer et al., 2004) seem to be opposite to the fact that antidepressants desensitize the 5-
HT1A autoreceptor. However, this can be explained by a study which showed that total 
5-HT1A receptor binding is decreased in the entire DRN in depressed suicides compared 
with controls (Boldrini et al., 2008). Whereas, analyses of specific areas of the DRN 
showed higher rostral and lower caudal 5-HT1A receptor binding (Boldrini et al., 2008). 
PET does not possess the necessary resolution to differentiate subnuclei within the RN 
and thus the decrease in 5-HT1A RN binding seen in most PET studies might be 
indicative of the 5-HT1A receptor function across the entire raphe (Savitz et al., 2009). 
 Involvements of the 5-HT2 receptors in depression have also been implicated. 
There are now several reports of higher 5-HT2 receptor binding in platelets of major 
depressed subjects and in the PFC of depressed suicide victims or depressed subjects who 
died from natural causes (Stanley and Mann, 1983, Biegon et al., 1990, Yates et al., 1990, 
Hrdina et al., 1993). This might be the result of compensatory upregulation of 
postsynaptic neurotransmitter receptors due to depletion of monoamines.  
Both the NE and 5-HT pathways do not act exclusively, but they have “cross-talks” 
between themselves as well as along with other neurotransmitter pathways, leading to 
enhanced or inhibited neurotransmitter release.  




1.1.2.2. Stress and depression: Involvement of the hypothalamic-pituitary-adrenal 
(HPA) axis 
A consistent finding in individuals with MDD is an increased level of 
glucocorticoids (GCs) resulting from how the body reacts to stress via activation of the 
HPA axis (Pariante and Lightman, 2008). Stress detected by the brain stimulates neurons 
in the paraventricular nucleus of the hypothalamus to secrete corticotrophin releasing 
factor, which stimulates the synthesis and release of adrenocorticotropic hormone (ACTH) 
from the anterior pituitary (Nestler et al., 2002, Dranovsky and Hen, 2006, Belmaker and 
Agam, 2008). ACTH then stimulates the synthesis and release of GCs from the adrenal 
cortex (Nestler et al., 2002, Dranovsky and Hen, 2006, Belmaker and Agam, 2008). 
Depression may be associated with progressive atrophy of the hippocampus as a result of 
GC mediated neurotoxicity (Sheline et al., 1996, Bremner et al., 2000, Stockmeier et al., 
2004).  
Administration of GCs suppressed the proliferation of both glia and neurons in the 
adult rat hippocampus (Gould et al., 1992). Adult monkeys exposed to intruder stress had 
decreased rates of granule cell proliferation in the hippocampus (Gould et al., 1998). 
High levels of GCs blocked the induction of long term potentiation (LTP), a cellular 
mechanism of learning and memory, in rats (Pavlides and McEwen, 1999). On the other 
hand, lower levels of corticosterone upregulated connectivity by facilitating LTP 
(Pavlides et al., 1993). Therefore, sustained elevations of GCs seen under conditions of 
prolonged and severe stress may damage hippocampal neurons (Gould et al., 1997, 
Reagan and McEwen, 1997, Gould et al., 1998). It reduces the amount of dendritic 
branching and causes a loss of the highly specialized dendritic spines where neurons 




receive their synaptic inputs (McEwen and Magarinos, 1997, Lambert et al., 1998, 
McKittrick et al., 2000, Radley et al., 2006). In addition, the lack of negative feedback 
due to hippocampal atrophy further activates the HPA axis, thereby increasing circulating 
levels of GCs and subsequent hippocampal damage, resulting in a viscous cycle (Nestler 
et al., 2002).  
 Interestingly, these abnormalities have been found to be corrected by 
antidepressant treatments (Maes and Smith, 1998, Pariante, 2006). Treatment with 
antidepressants in animal models increase neurogenesis (Malberg et al., 2000, Duman et 
al., 2001) as well as increase the dendritic aborizations of hippocampal neurons 
(Norrholm and Ouimet, 2001). This may be a mechanism by which antidepressants 
overcome stress-induced atrophy.   
 
1.1.2.3. Neurotrophic hypothesis of depression 
Limitations to the monoamine hypothesis arise from the fact that antidepressant 
treatments exert their mood-elevating effects only after prolonged administration (several 
weeks to months) (Katz et al., 2004, Mitchell, 2006), as well as the large number of 
depressed patients who do not respond to on-going antidepressant treatments, which 
serve to increase monoamine levels in the brain (Nestler et al., 2002). The current school 
of thought has now evolved to include downstream processes after antidepressant-
induced increase in neurotransmitter levels. The increase in presynaptic monoamine 
release results in the activation of a range of postsynaptic
 
receptors that are coupled to 
signal transduction mechanisms (Duman et al., 1999, Coyle and Duman, 2003, Racagni 
and Popoli, 2008).  They subsequently affect downstream gene expression and receptor 




turnover which probably accounts for the time lapse in symptomatic relief of 
antidepressant treatments. The neurotrophic hypothesis states that a deficiency in 
neurotrophic support may contribute to hippocampal pathology during the development 
of depression (Nestler et al., 2002). Many of the studies investigating the convergence 
between stress and monoamines in depression boil down to neuroplastic changes. An 
important neurotrophin, brain-derived neurotrophic factor (BDNF) is needed for the 
survival and guidance of neurons during development and it is required for the formation 
of new synaptic connections (Duman et al., 2000).  
In animal models, chronic treatment with antidepressants resulted in increased 
protein levels of BDNF (De Foubert et al., 2004). Local infusion of BDNF into the 
midbrain has been shown to have antidepressant effects in animal behavioral models of 
depression, such as learned helplessness and FST (Siuciak et al., 1997, Shirayama et al., 
2002). In addition, stress decreases the expression of BDNF, leading to stress-induced 
atrophy (Videbech and Ravnkilde, 2004), and this phenomenon could be reversed by 
antidepressant treatment (Videbech and Ravnkilde, 2004). Chronic ECT as well as 
antidepressant drugs, enhance the induction and prolong the expression of BDNF in 
treated animals (Nibuya et al., 1995). 
In humans, lower levels of serum BDNF have been found in untreated patients 
with MDD as compared with treated patients or healthy controls (Shimizu et al., 2003, 
Lee and Kim, 2008). Treatment with antidepressants resulted in normalization of serum 
BDNF levels (Shimizu et al., 2003). Similarly, postmortem analyses of suicide victims 
showed that BDNF levels were significantly reduced in the hippocampus and PFC as 
compared with non-suicide controls (Karege et al., 2005). ECT peformed in drug-




resistant depressed patients showed significantly higher serum levels of BDNF (Bocchio-
Chiavetto et al., 2006). In drug-treated suicide victims, however, BDNF levels were not 
significantly different from non-suicide controls. Hence, this further confirms the role of 
BDNF in the pathophysiology of depression as well as its importance in the mechanism 
of antidepressant actions.  
 The upstream regulation of BDNF is controlled by cAMP response element 
binding (CREB) protein, a transcription factor. It was speculated that the antidepressant 
action of CREB could be due to the induction of BDNF. In recent years, numerous 
literatures have shown that chronic antidepressant treatments are able to increase the 
expression, phosphorylation, transcriptional activity and protein levels of CREB (Nibuya 
et al., 1996, Dowlatshahi et al., 1998, Duman et al., 2000, Thome et al., 2000). These 
studies were complemented by data from postmortem brain analyses which showed 
reduced mRNA and CREB protein levels in brains of suicide subjects (Dwivedi et al., 
2003). All in all, despite the diversity of pharmacological actions between various 
antidepressant treatments, they seem to converge at the subcellular level to modulate the 
dynamics of neuroplasticity. 
 
1.1.3. Anatomical correlations in depression 
 Depression cannot be attributed to a single anatomical area. Instead, it involves 
various structures in the PFC and limbic regions of the brain, along with their 
interconnected circuits, forming an integrated network (Nestler et al., 2002, Maletic et al., 
2007, Drevets et al., 2008). They served to modulate learning and memory, mood 
changes, attention, executive function and so on (Maletic et al., 2007). These 




neuroanatomical areas include the dorsolateral PFC (DLPFC), orbital PFC, ventromedial 
PFC (VMPFC), anterior cingulate cortex (ACC), ventral striatum, amygdala and the 
hippocampus (Maletic et al., 2007). In this field of study, the ability to perform 
neuroimaging has served as a promising tool. Current brain imaging methodologies make 
it possible to identify gross circuits in the brain that are affected in depression (Bremner 
et al., 2002), as will be elaborated later on. 
 
1.1.3.1. PFC 
 Abnormalities in activity of the PFC in depression have been reported more 
frequently than for any other brain region (Davidson et al., 2002). Three major PFC 
regions have been associated with depression: the DLPFC region (involved in higher 
executive brain functions such as planning, working memory and emotional judgements 
(Grimm et al., 2008, Longe et al., 2009); the orbital PFC region (regulation of emotional 
and motivational behaviors, personality changes, disinhibition (Rajkowska, 2000a, 
Maletic et al., 2007); and the VMPFC region (involved in social conscience, moral 
responsibility, reward sensitivity and motivation (Milne and Grafman, 2001, Hansel and 
von Kanel, 2008, Longe et al., 2009).  
 In depressed subjects, metabolic studies measuring regional cerebral blood flow 
and regional cerebral glucose utilization have suggested overall reduced perfusion / 
metabolism in the PFC (Ito et al., 1996, Drevets et al., 2002, Kimbrell et al., 2002), with 
distinct hypoactivity in the DLPFC and hyperactivity in the VMPFC (Biver et al., 1994, 
Mayberg, 1994, Drevets, 1998). A study done recently using patients with brain lesions 
showed that bilateral VMPFC lesions were associated with low levels of depression, 




whilst bilateral DLPFC / dorsomedial PFC lesions were associated with higher levels of 
depression (Koenigs et al., 2008). Hence, this led to the hypothesis that both VMPFC and 
dorsal PFC have distinct roles in depression. VMPFC damage (inadvertently reducing the 
hyperactivity associated with depressive states) confers resistance to depression, whereas 
DLPFC damage (further abolishing the hypoactivity in depressive states) confers 
vulnerability (Koenigs et al., 2008). Results for the orbital PFC are more varied with 
some studies showing hyperactivity (Drevets, 1998) and others showing hypoactivity 
(Mayberg et al., 1990, Mayberg et al., 1992, Bremner et al., 2002) 
 Volumetric studies showed a reduction in PFC volume in depression (Drevets et 
al., 1997, Kumar et al., 1997, Kumar et al., 1998, Botteron et al., 2002). Other regions of 
the PFC, such as the orbital PFC showed volumetric reductions in middle-aged (Bremner 
et al., 2002) as well as geriatric (Lai et al., 2000) depressed patients as compared to 
controls.  
Postmortem studies have been consistent with morphologic changes in the PFC in 
depression. For example, decrease density of neurons and glia in the DLPFC and orbital 
frontal cortex are found in subjects with depression (Ongur et al., 1998, Rajkowska et al., 
1999). The same group of researchers further suggested that this decrease in density of 
neurons and glia may contribute to volumetric reductions in patients with depression 
(Rajkowska, 2000b).  In addition, such neuronal atrophy could result in a loss of 
neurotrophic factors in this region of the brain, resulting in a vicious cycle of neuronal 
cell death and inhibition of neurogenesis in depression and stress-induced depression 
(Duman et al., 2000, Sapolsky, 2000).  




 Conversely, antidepressant treatments were able to normalize the hypoactivity in 
the DLPFC as observed by functional magnetic resonance imaging (Fales et al., 2009). 
These patients showed a significant increase in recruitment of DLPFC (similar to controls) 
in response to unattended fear-related stimuli following antidepressant treatments (Fales 
et al., 2009). Antidepressant drugs are able to modulate the activity of NE neurons and 5-
HT neurons in their brainsteam nuclei (LC and DRN respectively), and since these 
neurons send afferent projections to the PFC, it is possible that the therapeutic effect of 
antidepressants is partly due to their indirect / direct actions on the neurons in the PFC.  
 
1.1.3.2. ACC 
 The ACC is part of the limbic system and has extensive connections with the 
neocortex. One of the major outputs from the ACC is a projection to the PFC (Davidson 
et al., 2002). Abnormalities in PFC activity in depression may thus arise as a 
consequence of the abnormal ACC activity, or may be intrinsic to the PFC, or both 
(Davidson et al., 2002).  The ACC plays important roles in cognitive and affective 
regulation, being involved in various brain functions such as problem solving, decision 
making and emotional control (Allman et al., 2001, Rushworth et al., 2007). The ACC 
comprises of two subdivisions: affective subdivision and cognitive subdivision (Devinsky 
et al., 1995). The affective subdivision is involved in emotional learning, assessments of 
motivational content and regulation of responses to stressful events, (Devinsky et al., 
1995, Bush et al., 2000, Davidson et al., 2002), whilst the cognitive subdivision is 
involved in the processing of cognitively demanding information (Devinsky et al., 1995, 




Davidson et al., 2002). It is believed that these two divisions play a functionally distinct 
role in MDD (Bush et al., 2000). 
 Similar to results showing hypoactivity in the DLPFC, several functional 
neuroimaging studies have shown reduced regional cerebral blood flow and cerebral 
glucose utilization in the ACC (Mayberg et al., 1992, Ito et al., 1996, Drevets et al., 1997, 
George et al., 1997, Drevets et al., 2002) and treatment with antidepressants normalized 
its hypoactivity (Bench et al., 1995, Buchsbaum et al., 1997).  Other studies demonstrated 
reduced ACC volume in MDD and bipolar disorder subjects using magnetic resonance 
imaging (MRI) (Drevets et al., 1997, Botteron et al., 2002, Coryell et al., 2005). In 
contrast, symptomatic improvements measured using the Hamilton Rating Scale for 
Depression after treatment with an antidepressant, fluoxetine, were associated with 
increased ACC volume (Chen et al., 2007). Furthermore, subjects with greater than 
median grey matter volume showed faster rates of improvement (Chen et al., 2007).  
 
1.1.3.3. Hippocampus 
 The hippocampus is critically involved in learning and memory (Dranovsky and 
Hen, 2006). Hippocampal neurons contain high levels of adrenal steroid receptors, 
thereby activation of the HPA axis in stress-induced depression affects the hippocampus 
directly (McEwen and Magarinos, 1997). In an animal study done to investigate the 
effects of stress duration on the hippocampus, it was found that a short period of chronic 
stress was sufficient to  induce neuronal atrophy (Lambert et al., 1998). As mentioned 
previously, multiple imaging studies have demonstrated a reduction in hippocampal 
volume in MDD subjects as compared to controls (Sheline et al., 1996, Bremner et al., 




2000, Sapolsky, 2000, Videbech and Ravnkilde, 2004). These results suggest that 
depression is associated with hippocampal atrophy causing a reduction in hippocampal 
volume due to GC-mediated neurotoxicity from stressful life events (Sapolsky, 2000, 
Davidson et al., 2002, Videbech and Ravnkilde, 2004). In addition, there is also reduced 
dendritic density / branching and neurogenesis (McEwen, 2001), culminating in an 
impairment in neuroplasticity.  
 These abnormalities have been found to be corrected by antidepressant treatments 
(Maes and Smith, 1998, Pariante, 2006) which serve to increase neurogenesis (Malberg et 
al., 2000, Duman et al., 2001) as well as dendritic aborizations of hippocampal neurons 
(Norrholm and Ouimet, 2001). This may be a mechanism by which antidepressants 
overcome the stress-induced cell death, perhaps involving various neurotrophic factors 
such as BDNF.   
 
1.1.3.4. Amygdala 
The amygdala is a key structure involved in recognizing sadness and fear. Patients 
with depression have impaired functioning in emotional tasks involving the amygdala. 
Depressed subjects displayed sustained amygdala reactivity on the emotional tasks 
(Siegle et al., 2007). Resting cerebral blood flow and glucose metabolism were also 
abnormally elevated in the amygdala (Drevets et al., 2002, Drevets, 2003). In the left 
amygdala, healthy humans increase cerebral blood flow in the amygdala during exposure 
to pictures of faces expressing fear (relative to viewing either smiling or neutral faces), 
but this response is blunted in depressed subjects (Drevets, 2001). Following 
antidepressant treatment, the amygdala activity normalizes (Sheline et al., 2001, Drevets 




et al., 2002). The reduction in amygdala metabolism during treatment correlated 
positively with both clinical improvement (as measured by the decrement in depression 
ratings) and reduction in stressed plasma cortisol concentrations (Drevets et al., 2002). 
 
1.1.4. Treatment modalities of depression 
1.1.4.1. Antidepressants 
The American Psychiatric Association’s Practice Guideline for the Treatment of 
Patients with MDD advices that pharmacotherapy should be continued for at least 6-8 
weeks. It can be supplemented by psychotherapy. If no favorable response is obtained 
after 8 weeks, clinicians should consider changing the antidepressants, intensifying 
psychotherapy or administering ECT. Response of partial responders can be augmented 
by increasing the dose of antidepressant used, changing the antidepressant, intensifying 
psychotherapy or administering ECT. The use of particular antidepressants will depend 
on the age group of the patients and the presence of other co-morbidities. 
 Many antidepressant medications work by interacting with 5-HT or NE reuptake 
mechanisms, thus increasing synaptic levels of these monoamine neurotransmitters and 
inducing changes in signal transduction cascades (Palazidou, 1997, Coyle and Duman, 
2003, Donati and Rasenick, 2003). Most antidepressants block monoamine reuptake, 
some block α2 receptors and others block the enzyme MAO. Ultimately, all 
antidepressants serve to increase the availability of monoamine neurotransmitters in the 
synaptic cleft. As mentioned earlier, all available antidepressants exert their mood-
elevating effects only after chronic treatment (Katz et al., 2004, Mitchell, 2006), even 
though increased levels of monoamine in the synapses can be detected within hours after 




antidepressant administration. Therefore, this signifies some form of intracellular events 
taking place. It has been evidenced that antidepressants enhance 5-HT / NE signaling, 
thereby enhancing the cAMP signal-transduction cascade and increasing the activity and 
expression of CREB, which in turn increases BDNF (Duman et al., 1997). To date, 
chronic treatments with antidepressants and ECT have all been shown to increase 
neurogenesis (Duman et al., 2000, Malberg et al., 2000). It is proposed that 
antidepressants, no matter how diversified their initial pharmacological actions, 
eventually cause critical genes to be activated (e.g. BNDF) or inactivated (Stahl, 2008).  
 
Antidepressants can be classified according to their pharmacological actions: 
(1) The classical antidepressants – MAO inhibitors (MAOIs) and heterocyclic 
antidepressants 
MAOIs are the oldest class of antidepressants and they act by inhibiting the 
activity of the enzyme MAO, thus preventing the breakdown of monoamine 
neurotransmitters thereby increasing their availability in the synaptic cleft for action on 
postsynaptic receptors. MAO exists in 2 subtypes, A and B (Pletscher, 1991, Potter and 
Hollister, 2009). MAO-A is the enzyme subtype involved in inactivation of monoamine 
neurotransmitters (5-HT, NE and DA) and it is closely linked to depression (Potter and 
Hollister, 2009). Both forms are inhibited by the original irreversible, nonselective 
MAOIs (e.g. iproniazid, isoniazid, phenelzine, tranylcypromine). One of the most 
troublesome side effect of this nonselectivity is the fact that by inhibiting MAO-A, they 
also inhibit the breakdown of the amines closely linked to the control of blood pressure 
(e.g. NE) (Potter and Hollister, 2009). As a result, when patients on MAOIs eat food rich 




in tyramine (such as cheese), a “cheese reaction” occurs, releasing NE and other 
sympathomimetic amines (Pletscher, 1991, Potter and Hollister, 2009). These amines are 
not able to be metabolized and can accumulate to dangerously high levels causing 
dangerous elevations in blood pressure, known as a hypertensive crisis. The need to 
control one’s diet and medication intake strictly has led to the demise of these older 
nonselective irreversible MAOIs.  
A newer class of MAOIs, the reversible inhibitors of MAO-A (RIMAs) (e.g. 
moclobemide, brofaromine) were then developed. By being reversible inhibitors, the 
presence of sympathomimetic amines generated from tyramine will displace RIMAs from 
MAO-A, thus preventing their accumulation. 
Tricyclic antidepressants (TCAs) (imipramine, amitriptyline, nortriptyline, 
doxepine, desipramine) are so called because of their characteristic three-ring nucleus and 
they possess a multitude of activity, including 5-HT reuptake inhibitor activity, NE 
reuptake inhibitor activity, anticholinergic activity, α1-adrenergic antagonist activity and 
antihistaminic activity (Stahl, 2008, Potter and Hollister, 2009). TCAs bind to nearby 
allosteric sites on the neurotransmitter reuptake transporters and make them less able to 
bind to neurotransmitters, thus blocking the synaptic reuptake of the neurotransmitters. 
The degree and selectivity of inhibition of the SERT vs NET, as can be seen by their 
binding efficiency to the reuptake transporters, differ across the family of TCAs (Tatsumi 
et al., 1997). For example, TCAs such as imipramine, amitriptyline, nortriptyline, show 
more potent inhibition of the SERT as compared to NET; whereas desipramine is a more 
potent inhibitor of the NET (Tatsumi et al., 1997). Blockade of the 5-HT and NE 
reuptake pumps account for the therapeutic actions of these drugs, whilst the other 




pharmacological properties account for their side effects (Stahl, 2008, Potter and 
Hollister, 2009). Their side effects include dry mouth, blurred vision, urinary retention, 
memory disturbance, constipation (due to their anticholinergic activities); orthostatic 
hypotention (due to their α1-adrenergic antagonist activities); sedation (due to their 
antihistaminic activities). TCAs have a very narrow therapeutic window and 
concentrations of 5 to 10 times their therapeutic dose can cause potentially serious side 
effects on cardiac conduction (Palazidou, 1997, Kando et al., 2008). In view of such side 
effects, the use of TCAs has now been relegated to second line and they are used when 
other forms of antidepressant therapy fails.  However, TCAs still show usefulness in 
severe melancholic depression (Boyce and Judd, 1999, Kando et al., 2008). 
 Maprotiline, mianserin and mirtazapine (also known as a norepinephrine and 
specific serotonin antidepressant) are tetracyclic antidepressants. Amongst the classical 
antidepressants, maprotiline exhibits the most potent inhibition of the NET while having 
no apparent influence on the SERT (Tatsumi et al., 1997, Lenox and Frazer, 2002). At the 
same time, maprotiline (similar to the tricyclics) has an affinity for the histamine receptor, 
muscarinic cholinergic receptor, α1 receptor and therefore has similar adverse effects 
(Brunello et al., 2002). It is also associated with a higher incidence of seizures than 
standard TCAs and it is contraindicated in patients with a history of seizures (Kando et al., 
2008).  Mirtazapine and mianserin exhibit α2 antagonistic activity (blocking of 
presynaptic α2 heteroreceptors), thereby disinhibiting both 5-HT and NE release (Lenox 
and Frazer, 2002, Stahl, 2008). Mianserin has been mostly phased out in favor of 
mirtazapine. In a major systematic review looking at the efficacy and tolerability of 12 
new-generation antidepressants, mirtazapine was found to be more effective as compared 




to majority of the included selective serotonin reuptake inhibitors (SSRIs), dual serotonin 
and norepinephrine reuptake inhibitors (SNRIs) and reboxetine, however, it ranked 
average in tolerability (Cipriani et al., 2009). The lack of anticholinergic activity with 
mirtazapine may be of advantage in some patient populations where urinary retention, 
constipation, blurred vision and/or confusion are likely to be of significance. 
 
 (2) SSRIs 
 SSRIs were developed in response to the need for better tolerated antidepressants 
with safer side effect profiles. The first SSRI to be released was fluoxetine (Prozac) 
(Steffens et al., 1997, Potter and Hollister, 2009) and till date, this class of 
antidepressants has remained the most widely used. SSRIs (fluoxetine, paroxetine, 
sertraline, citalopram, fluvoxamine) selectively inhibit SERTs. This causes an increase in 
5-HT predominantly in the somatodendritic area of 5-HT neurons (Stahl, 2008). 
Sustained increases in 5-HT due to chronic administration of SSRIs will eventually cause 
desensitization of the somatodendritic 5-HT1A autoreceptors which in turn increases 
release of 5-HT from the axon terminals since neuronal impulse flow is no longer 
inhibited (Stahl, 2008). 
 Despite being called SSRIs, no two SSRIs have identical secondary 
pharmacological characteristics and all have activity at other receptors. Fluoxetine and 
paroxetine are potent inhibitors of the enzyme cytochrome P450 2D6, which also 
happens to be important in the deactivation of TCAs (Harvey and Preskorn, 1995, Stahl, 
2008, Sghendo and Mifsud, 2012). Hence, if these SSRIs and TCAs are given together or 
if there is a switching between TCAs and SSRIs (without adequate wash-out time), there 




might be dangerous build up of plasma levels of TCAs (Harvey and Preskorn, 1995, Stahl, 
2008). Fluoxetine also blocks 5-HT2C receptors (which have inhibitory effect on NE and 
DA release via gamma amino-butyric acid (GABA) interneurons), thereby enhancing its 
therapeutic effects (Ni and Miledi, 1997, Stahl, 2008). At high doses, fluoxetine has weak 
selective norepinephrine reuptake inhibitor (NRI) properties (Sanchez and Hyttel, 1999, 
Stahl, 2008, Sghendo and Mifsud, 2012). Along with sertraline, paroxetine has the most 
potent inhibitory effect on 5-HT reuptake. It also has mild activity on the muscarinic 
cholinergic receptor (most potent amongst the SSRIs) and NRI property at high doses 
(highest amongst the SSRIs) (Hyttel, 1994, Stahl, 2008, Sghendo and Mifsud, 2012).  
 Results of a few early meta-analyses studies comparing the efficacy and 
tolerability of SSRIs with TCAs showed that there were no differences in efficacy 
between these two classes of drugs (Steffens et al., 1997, Anderson, 2000, Arroll et al., 
2005). Another study comparing the efficacy of paroxetine and maprotiline in depressed 
outpatients showed equal effectiveness between both drugs but their side effect profiles 
were different, as maprotiline patients had more anticholinergic and paroxetine patients 
more SSRI-typical side-effects (Szegedi et al., 1997). In the same systematic review as 
mentioned above, two SSRIs, sertraline and escitalopram have been ranked with similar 
efficacy to mirtazepine as the most efficacious antidepressant amongst the 12 most 
popular antidepressants prescribed in practice (Cipriani et al., 2009). They showed the 
best profile of acceptability, leading to fewer discontinuations (Cipriani et al., 2009). 
Sertraline is recommended as the best choice for starting antidepressant treatment in 
adults due to its overall edge in tolerability, cost and efficacy (Cipriani et al., 2009). 




 Side effects of SSRIs include sexual dysfunction and gastrointestinal disorders 
(Ferguson, 2001). SSRIs in overdose are far safer than TCAs despite 5-HT syndrome 
being common (Barbey and Roose, 1998, Isbister et al., 2004). In therapy, the use of 
SSRIs has largely replaced that of TCAs and tetracyclic antidepressants as first-line 
therapy due to their better overall tolerability profile (Steffens et al., 1997, Anderson, 
2000, Ferguson, 2001). It was shown that significantly more TCA-treated than SSRI-
treated subjects dropped out due to either lack of efficacy or adverse reactions (Steffens 
et al., 1997).  An additional advantage of SSRIs over TCAs is a reduced risk of drug-drug 
interactions (Ferguson, 2001). All SSRIs have a wide therapeutic index and they do not 
affect cardiac conduction. Patients have survived overdoses of each of the SSRIs that 
were many times their usually effective antidepressant doses without serious toxicity. In 
general, the SSRIs have a wider spectrum of clinical usage in addition to depression. 
They have also been approved for use in anorexia, anxiety, aggression and obsessive 
compulsive disorders, and some are marketed for some of these indications (Palazidou, 
1997, Potter and Hollister, 2009). 
 
(3) NRIs 
 Although some older antidepressants, such as desipramine (TCA) and maprotiline 
inhibit NE reuptake more potently as compared to 5-HT, they are not exclusive in their 
pharmacological actions as they have antagonistic effects at other receptors. Reboxetine 
is a relatively new and the first specific NRI, which, unlike desipramine or maprotiline, 
has significant affinity for NET and weak affinity for other nonspecific receptors (Wong 
et al., 2000). NE regulation may be more closely correlated with improvement in energy, 




interest, agitation and hopelessness, whilst 5-HT regulation involves control of affects, 
aggression, sleep and appetite (Kadhe et al., 2003). Reboxetine may thus be useful for a 
specific subset of depressed patients who exhibit comorbid anxiety. However, it’s 
application for approval has been rejected by the US Federal Drug Administration, 
although it is still being marketed in many european countries (Eyding et al., 2010). 
Reboxetine, also one of the 12 antidepressants analysed in the Cipriani meta-analysis of 
antidepressants, was significantly less efficacious than all other antidepressants tested and 
had the highest trial dropout rates (Cipriani et al., 2009). Therefore, reboxetine is not 
recommended as a routine first-line treatment for major depression.  
 
(4) SNRIs 
 Examples of SNRIs include venlafaxine and duloxetine. Venlafaxine is an SNRI 
which has a much safer side effect profile as compared to TCAs (Jain, 2004). It may 
provide a faster onset of efficacy and higher rates of remission than the older TCAs and 
MAOIs while avoiding their intolerable side effects (Andrews et al., 1996, Jain, 2004). 
However, venlafaxine itself is associated with an increased risk of sustained hypertension 
at high doses (Jain, 2004). In the Cipriani review, venlafaxine was shown to be more 
efficacious as compared to other antidepressants such as fluoxetine, paroxetine, 
reboxetine and duloxetine, however, it was weaker in terms of overall acceptability 
(dropout rate) (Cipriani et al., 2009). However, data for duloxetine, another SNRI, was 
not as promising because it was shown to be less effective (alongside reboxetine, 
paroxetine and fluvoxamine) in the same systematic review. 
 





 ECT is a treatment in which seizures are electrically induced in anaesthetized 
patients for therapeutic effects (Lisanby, 2007, Cipriani et al., 2009). According to the 
latest 2010 Practice Guidelines for the Treatment of Patients With MDD dished out by 
the American Psychiatric Association, ECT should be considered as the treatment of 
choice for severe MDD coupled with psychotic features, a good response to previous 
ECT, a lack of response to antidepressant medications after a trial period, as well as 
situations when a rapid antidepressant response is needed. ECT is typically administered 
2–3 times a week (Lerer et al., 1995, Lisanby, 2007). More frequent administration of 
ECT also increases the severity of its cognitive side effects. The total number of 
treatments vary between approximately 6 to 12, depending on the severity of the patient’s 
symptoms and the rapidity of the response (Lisanby, 2007). ECT is generally a very safe 
treatment. The main side effect is short term memory loss, also known as anterograde 
amnesia, which usually resolves soon after ECT is completed (Sackeim et al., 1986, 
Lisanby, 2007). Retrograde amnesia happens when patients have gaps in recent memories 
that occurred before the treatment and it is more persistent, lasting for a longer period of 
time (sometimes several months to years) after ECT.   
 A systematic review and meta-analyses of randomised controlled trials and 
observational studies published by the UK ECT Review group compared ECT to placebo 
and antidepressant drugs (Group, 2003). They concluded that ECT was more effective 
than pharmacotherapy, and this is also supportred by other studies (Parker et al., 1992, 
Group, 2003, Pagnin et al., 2004). Plasticity studies have shown that ECT increases 
BDNF expression (Chen et al., 2001, Dias et al., 2003), similar to antidepressant 




treatments, hence suggesting a common molecular mechanism of action of modulating 
neuronal plasticity. 
 
1.1.4.3. Transcranial magnetic stimulation (TMS) 
 TMS involves the application of a magnetic flux to induce secondary currents in 
the brain and action potentials in neurons, and is used to map alterations in connectivity 
between cortical areas and / or their spinal projections (Barker et al., 1985, Kobayashi 
and Pascual-Leone, 2003, Bestmann, 2008). The magnetic field causes electric currents 
to be generated within the tissue, which in turn causes depolarization of the cell 
membrane. The magnetic field strength falls off with the square of the distance from the 
stimulating coil, therefore, the stimulus strength is the highest close to the coil surface. 
The main advantage of double coils (figure of 8 shape coils) over circular coils is that the 
induced tissue current is at its maximum directly under its centre, where the two windings 
meets, giving a more accurately defined area of stimulation. 
 Repetitive TMS (rTMS) induces enduring changes in cortical function and 
plasticity-like changes, affecting processes such as neural repair, learning and memory 
(Hallett, 2000, Kobayashi and Pascual-Leone, 2003, Bestmann, 2008). Depending on 
stimulation parameters, induced electrical currents depolarize neurons resulting in 
changes in cortical function and behavior (Ziemann, 2004) and muscle activation 
(Kapogiannis and Wassermann, 2008). High frequency rTMS stimulation (>5Hz) 
enhances motor excitability, whereas low frequency stimulation (1 Hz) depress cortical 
excitability (Pascual-Leone et al., 1994, Chen et al., 1997, Pascual-Leone et al., 1998, 
Rossi et al., 2000). 




According to the American Psychiatric Association guidelines for antidepressant 
treatment, TMS was cleared by the FDA in 2008 for use in individuals with MDD who 
have not had a satisfactory response to at least one antidepressant trial in the current 
episode of illness. Antidepressant effect of rTMS has been demonstrated in many studies 
(Padberg et al., 2002, Stern et al., 2007, Avery et al., 2008). Currently, there are two 
approaches with regards to the treatment of depression with rTMS: repetitive high 
frequency stimulation and repetitive low frequency stimulation. The latter technique is 
less well studied, but appears to have beneficial effects similar to that of high frequency 
stimulation. A recent meta-analyses concluded that patients treated with high-frequency 
rTMS over the left DLPFC showed improved outcomes as compared to control subjects 
(Schutter, 2009). In addition, rTMS rescued defects in LTP in rats subjected to the FST, 
suggesting that rTMS treatment rescued impaired synaptic efficiency caused by 
depression (Kim et al., 2006). Increased levels of BDNF mRNA were detected in the 
hippocampal area of the rat brain after rTMS (Muller et al., 2000). Similarly, rTMS was 
able to increase levels of serum BDNF in depressed patients (Yukimasa et al., 2006, 
Zanardini et al., 2006).  
An advantage of rTMS over ECT is the fact that the patients are alert and do not 
need to be anaesthetized, hence minimizing risks associated with anaesthetization. 
Studies comparing the efficacy of rTMS and ECT have found rTMS to be either less 
effective (Eranti et al., 2007, McLoughlin et al., 2007) or comparable in efficacy to ECT 
(Janicak et al., 2002, Rosa et al., 2006). Across all studies, rTMS was well tolerated and 
adverse events attributed to rTMS were generally mild with transient scalp discomfort 
and headaches being the most commonly reported side effects (Bae et al., 2007).  A more 




serious side effect of rTMS is its potential to induce a seizure, however, a review 
studying the safety of rTMS in epilepsy patients reported that seizures only occurred in 
four patients (out of all the patients from 26 studies) and three out of the four were the 
patients’ typical seizures and were associated with low frequency rTMS (Bae et al., 2007). 
A single case of seizure possibly arising from high frequency rTMS was reported (Bae et 
al., 2007). There were no reported cases of rTMS-related episodes of status epilepticus 
(Bae et al., 2007). Hence, it was concluded that rTMS appears to be nearly as safe in 
patients with epilepsy as in nonepileptic individuals (Bae et al., 2007).  
 
1.1.5. Animal models used in assessing antidepressant activity 
 Animal models assessing antidepressant activity in rodents are indispensable tools 
in the search for new antidepressant drugs or investigating any form of antidepressant 
effects. The validity of an animal model lies in its reliability, reproducibility and 
predictivity. Current models are not perfect as many human emotions displayed in 
depression, such as feelings of worthlessness, suicidal behavior cannot be replicated in 
animal models (Nestler et al., 2002). In addition, many of the tests show antidepressant 
activity in rodents after acute administration of antidepressants, whereas in humans, 
chronic administration of antidepressants is required before any form of symptomatic 
relief is observed. Animals models used include the FST, tail suspension test (TST), 
olfactory bulbectomy, learned helplessness and chronic mild stress (CMS) and so on, but 
the most widely used for antidepressant screening is the FST (Cryan and Mombereau, 
2004). Other animal models such as novelty suppressed feeding, also known as novelty-
induced hypophagia and marble burying are sensitive to chronic administration of 




antidepressants, however, they reflect the anxiolytic effects of antidepressants which are 
not seen in some antidepressants (Dulawa and Hen, 2005) 
 
1.1.5.1. FST 
 FST, introduced by Porsolt, is based on the observation that rodents forced to 
swim in a cylinder filled with water of which they cannot escape from, will adopt a 
characteristic immobile posture following initial escape-oriented movements (Porsolt et 
al., 1977). This behavior is proposed to be analogous to that of behavioral despair seen in 
depression (Krishnan and Nestler, 2008). It is the most frequently used experimental 
paradigm for detecting antidepressant activity due to its reproducibility across 
laboratories and its ability to detect activity in a wide range of clinically effective 
antidepressants (Cryan et al., 2002) with an added advantage of only subjecting animals 
to one stressful situation. Antidepressant treatments are usually given 30-60 mins prior to 
the test and the duration of immobility will be scored. An antidepressant effect is 
observed when the animals actively persist in escape-directed behaviors for longer 
periods of time as compared to controls (Porsolt et al., 1977, Cryan et al., 2002, Cryan et 
al., 2005b).  
 However, it was found that the FST was not able to reliably detect antidepressant 
effects of SSRIs, which are the most widely prescribed antidepressant drugs today 
(Borsini, 1995). It was subsequently modified by increasing the water depth as well as 
including various behavioral measurements: climbing, swimming and immobility (Cryan 
et al., 2002). In particular, swimming shows greater sensitivity to 5-HT compounds such 




as SSRI antidepressants, whilst climbing is more sensitive to TCAs and NE related 
antidepressants (Cryan et al., 2002, Cryan et al., 2005b).  
 Another initial drawback to the FST as well as the TST (described below) was the 
fact that acute antidepressant treatments were able to reduce immobility timing whereas 
in actual practice, it could take weeks for the same antidepressant to elevate mood in 
depressed humans (Cryan et al., 2002, Petit-Demouliere et al., 2005). Yet, recent studies 
have demonstrated that chronically administered antidepressant drugs were able to elicit 
an effect on immobility during FST as well, thereby increasing the face validity of FST 
(Detke et al., 1997, Conti et al., 2002, Reneric et al., 2002, Dulawa et al., 2004). The FST 
may not be a direct replicate of depression itself, as depression is characterized by a very 
heterogenous etiology and numerous symptomatic manifestations. However, it still 
persists as the primary screening test for antidepressants, and, for this purpose, it serves 
its role well. 
 
1.1.5.2. TST 
 The theory of TST is similar to that of FST, wherein the behavioral despair 
activity is being observed. Antidepressants are administered 30 mins before the test and 
the animals are suspended by their tails for 6 mins while their immobility duration is 
recorded (Steru et al., 1985). Acute antidepressant treatments decrease the immobility 
scores. This test is able to detect a wide range of antidepressants rapidly with great ease 
of use and reliability, irrespective of their underlying mechanism, unlike the original FST 
which was not able to detect SSRI antidepressant activity reliably (Cryan et al., 2005a). 
In addition, it is easily subjected to automation and the animals are not exposed to 




stressful hypothermia (Cryan and Mombereau, 2004). A major drawback of the TST, 
however, is that certain strains of mice (e.g. C57Bl/6) have a tendency to climb their tails, 
therefore making accurate interpretation of behavioral measures difficult (Mayorga and 
Lucki, 2001) and its sensitivity to short-term antidepressant effects (Cryan et al., 2005a). 
However, it is still not as well characterized as the FST and more analysis will be 
required to increase the validity of the test (Cryan et al., 2005a). 
 
1.1.5.3. Learned helplessness test 
 This test is based on the fact that animals demonstrate escape deficits in aversive 
but escapable situations after being subjected to repeated unavoidable shocks (Overmier 
and Seligman, 1967). The animals are placed in Plexiglas tubes and unpredictable, 
inescapable footshocks are delivered following which they develop learned helplessness 
(Overmier and Seligman, 1967, Vollmayr and Henn, 2001, Chourbaji et al., 2005). The 
animals are tested again 24 hours later in chambers with appropriate escape routes/ 
escape responses are placed and their latency to escape is measured (Overmier and 
Seligman, 1967, Vollmayr and Henn, 2001, Chourbaji et al., 2005). Antidepressant 
agents administered will be able to reverse these escape deficits. It can be used in studies 
monitoring chronic, rather than acute antidepressant drug administration (Ikezu and 
Gendelman, 2008). The major drawbacks of the learned helplessness model are that most 
of the depressive-like symptoms it mimics do not persist beyond 2-3 days after stopping 
administration of the uncontrollable shock and the acute stress mimics post traumatic 
stress disorder more than major depressive disorder (Cryan and Mombereau, 2004, 
Goodwin and Jamison, 2007, Ikezu and Gendelman, 2008).  In addition, this model has 




only moderate ease of use and reliability in contrast to FST and TST which are extremely 
easy to use and have high reliabilities (Cryan et al., 2002).  
 
1.1.5.4. Chronic mild stress test 
The chronic mild stress model involves subjecting rats or mice to unpredictable “mild” 
stressors intermittently over the course of 2-4 weeks (Cryan and Mombereau, 2004, 
Goodwin and Jamison, 2007, Ikezu and Gendelman, 2008). These stressors include soiled 
bedding, changing light-dark cycles, food deprivation, predator noises, tilted cages 
(Goodwin and Jamison, 2007, Ikezu and Gendelman, 2008). Consumption of a sweet 
sucrose drink is generally decreased in these stressed animals (modelling anhedonia or 
loss of pleasure in depression), and this is returned to normal consumption by chronic 
administration of antidepressant drugs (Willner, 1997). The main advantage of this model 
is its relationship to chronic stress, which may be more relevant to major depressive 
disorder (Reid et al., 1997, Goodwin and Jamison, 2007, Ikezu and Gendelman, 2008). 
However, it is difficult to carry out, very labour and time intensive and has poor 
reproducibility, hence, leading to its dwindling usage (Willner, 1997). Most 
characterization with the chronic mild stress model has been done in rats and it still 
remains to be determined whether it can be replicated successfully in mice (Cryan and 
Mombereau, 2004). 
 




1.2. General introduction to brain lipids 
1.2.1. Glycerophospholipids 
1.2.1.1. Introduction 
 The brain contains the second highest concentration of lipids 
(glycerophospholipids, sphingolipids, cholesterol) in the body, after adipose tissue, with 
phospholipids making up 60% of the dry weight of the brain (Horrobin, 2001). 
Glycerophospholipids make up majority of cellular membrane lipid composition, 
accounting for 20-25% of the dry weight in an adult brain (Farooqui and Horrocks, 2007). 
They are organized in lipid bilayers and each molecule consists of a 3-carbon glycerol 
backbone, fatty acids, phosphoric acid and a nitrogenous base (Figure 1.1) (Farooqui and 
Horrocks, 2007).  
 
 Figure 1.1 Structure of glycerophospholipids Adapted from Farooqui et al, 
2007. 
 




 The 1st and 2nd carbons (called sn-1 and sn-2) are attached to fatty acids (R1 and 
R2 respectively). The R1 fatty acid is often saturated or monounsaturated (palmitic acid, 
oleic acid stearic acid), whilst the R2 fatty acid is almost always a highly unsaturated 
fatty acid and a member of the omega-6 (arachidonic acid (AA)) or omega-3 (DHA, 
eicosapentaenoic acid (EPA)) series (Horrobin, 2001). A phosphorus atom and a 
relatively water soluble nitrogenous headgroup, usually inositol or choline or serine or 
ethanolamine is attached to the third position (sn-3), forming the different classes of 
glycerophospholipids (Horrobin, 2001). If the fatty acid at the sn-1 position is attached to 
the glycerol backbone via a vinyl ether linkage, a unique group of glycerophospholipids 
known as plasmalogens are formed (Farooqui and Horrocks, 2001b). The most abundant 
glycerophospholipids in mammalian tissues are phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), phosphatidylserines (PS) and phosphatidylinositols 
(PIs) (Farooqui et al., 2000a, Farooqui and Horrocks, 2007). They are amphipathic 
molecules comprising of a polar headgroup (phosphate group and nitrogenous base) and a 
non-polar hydrocarbon tail. The degree of unsaturation in the hydrocarbon tails 
determines the membrane order, packing pattern and fluidity of the membrane. Increased 
number of unsaturated carbon-carbon bonds creates more “kinks” in the structure, 
making it less able to pack tightly, therefore increasing the fluidity of the membrane. 
Phospholipids in neural membranes are asymmetrically distributed across the plane of the 
plasma membrane, with PEs and PSs concentrated on the inner leaflet whilst PCs and 
sphingolipids are concentrated in the outer leaflet (Porcellati, 1983). 
Glycerophospholipids homeostasis is based on a balance between their synthesis 
pathways, catabolism and resynthesis by reacylation (Porcellati, 1983). 




1.2.1.2. Biosynthesis of glycerophospholipids 
Phosphatidic acid (PA) is an important intermediate, it being the main precursor of all 
neural membrane glycerophospholipids (Farooqui and Horrocks, 2007). Hydrolysis of 
PAs by the enzyme PA phosphatase produces diacylglycerols (DAGs) which 
subsequently go on to produce triacylglycerols (TAGs), PCs and PEs via the Kennedy 
pathway (Figure 1.2) (Farooqui and Horrocks, 2007). The Kennedy pathway forming 
either PCs or PEs involves three enzymic steps catalyzed by choline / ethanolamine 
kinases, phosphocholine or phosphoethanolamine cytidyltransferases, and 1,2-DAG 
phosphocholine transferase or 1,2-DAG phosphoethanolamine transferase (Kennedy and 
Weiss, 1956, Farooqui and Horrocks, 2007). PE can be methylated to form PC and both 
PE and PC can be converted to PS via a base exchange reaction with serine (Farooqui and 
Horrocks, 2007). PAs can also form cytidine diphosphate DAGs (CDP-DAGs) via the 
CDP-DAG pathway, leading to the synthesis of phosphatidylglycerols (PG), cardiolipins, 
PIs and PSs. 




Figure 1.2. Biosynthesis of glycerophospholipids in the brain. (1) 
Ethanolamine kinase; (2) CTP, phosphoethanolamine cytidylyltransferase; 
(3) CDP-ethanolamine, 1,2-DAG, phosphoethanolamine transferase; (4) 
Phosphatidate cytidylyltransferase; (5) Diacyiglycerol kinase; (6) PA 
phosphatase; (7) Choline kinase; (8) CTP, phosphocholine 
cytidylyltransferase; (9) CDP-choline, 1,2-DAG phosphocholine 
transferase; (10) PE N-methyltransferase; (11) DAG acyltransferase; (12) 
and (13) PS synthase; (14) PS decarboxylase. Adapted from Farooqui et al, 
2007.   
  
1.2.1.3. Catabolism of glycerophospholipids  
 Brain glycerophospholipids are constantly remodeled post-synthesis via 
hydrolysis and reacylation (Land’s cycle) to maintain a dynamic membrane environment. 
Glycerophospholipids are hydrolyzed by a group of enzymes called phospholipases, 




which play critical roles in generating lipid-derived second messengers. Phospholipases 
are classified based on their site of attack (Figure 1.3) (Wilton, 2008).  
 
 
Figure 1.3 Site of attack of phospholipase enzymes Adapted from 
Farooqui et al, 2000a.  
 
 Phospholipase A1 (PLA1) and phospholipase A2 (PLA2) act on the fatty acid ester 
bond at the sn-1 or sn-2 position respectively, releasing free fatty acids (FFAs) and 
lysoglycerophospholipids (Farooqui et al., 2000a). FFAs are  active signaling molecules 
and their action can be terminated by conversion to their coenzyme A derivatives, 
forming fatty acyl-coenzyme A (Horrobin, 2001). These fatty acyl-coenzyme A can be 
reacylated back to form glycerophospholipids by reaction with lysoglycerophospholipids 
via the action of various acyl-CoA:lysophospholipid acyltransferases (Lands, 1958). 
Different acyl-CoA:lysophospholipid acyltransferases have different specificity for the 
type of fatty acid-CoA being transferred. Therefore, various FFAs can be introduced by 
this route, thereby modifying the fatty acid side chains of glycerophospholipids. 
Phospholipase C hydrolyzes the phosphodiester bond at the sn-3 position, forming DAGs 
and a phosphobase (Farooqui et al., 2000a). It is particularly important for signal 




transduction pathways, for example, enzymatic hydrolysis of PI 4,5-bisphosphate by 
phospholipase C forms DAG and inositol triphosphate (IP3), which are secondary 
messengers important for the mobilization of intracellular calcium and activation of 
protein kinase C (Berridge and Irvine, 1984). Finally, phospholipase D is responsible for 
removal of the headgroup by cleaving glycerophospholipids into PA and a freebase 
(Farooqui et al., 2000a).  
 
1.2.1.4. Role of glycerophospholipids 
 Lipids are essential components of cellular membranes, serving to delineate 
cellular compartments and form semi-permeable barriers. The most obvious role of 
glycerophospholipids is the structural properties which they impart on cellular 
membranes. The ratios of different classes of glycerophospholipids vary between various 
organelles and affect membrane fluidity, packing, and curvature. For example, PEs and 
PSs contain more of DHA, a polyunsaturated fatty acid (PUFA) side chain at the sn-2 
position, whilst PCs contain more saturated fatty acids (Farooqui and Horrocks, 2007). 
The increased degree of unsaturation will result in membranes having greater fluidity due 
to reduced packing as well as decreased melting temperature.  
 Glycerophospholipids and plasmalogens especially serve as a reservoir for the 
generation of various lipid mediators, such as platelet activating factor and eicosanoids. 
For instance, activation of PLA2 and its action on certain glycerophospholipids releases 
AA, a FFA, which can be further metabolized via lipoxygenase (LOX) and 
cyclooxygenase (COX) enzymes to form prostaglandins, leukotrienes, thromboxanes 
(collectively known as eicosanoids) that serve as intracellular second messengers 




important for regulation of cell proliferation, oxidative stress, and inflammation 
(Farooqui, 2009b). Under pathological conditions of oxidative stress such as ischemia, 
excessive amounts of glycerophospholipid hydrolysis with resultant accumulation of 
eicosanoids activate astrocytes and microglia releasing inflammatory cytokines which in 
turn propagate and intensify neuroinflammation causing increasing neuronal damage 
(Ong et al., 2010). Lysophospholipids, the other product of PLA2-catalyzed reactions, 
play a role in a wide range of cellular processes involving membrane–protein or 
membrane–membrane interactions and they are precursors for platelet activating factor 
(Fuller and Rand, 2001). In addition, as mentioned earlier, the action of  phospholipase C 
on PI 4,5-bisphosphate generates DAG and IP3 (Farooqui and Horrocks, 2007). IP3 
stimulates the release of calcium which then triggers various events of calcium signaling 
(Farooqui and Horrocks, 2007). DAG stimulates protein kinase C which in turn is able to 
phosphorylate various proteins important for cellular functions. 
 Glycerophospholipids also play a role in apoptosis. The distribution of lipids in 
the cell membrane is such that PCs and sphingolipids are located in the outer leaflet of 
the plasma membrane, whilst PEs and PSs occur primarily in the inner leaflet (Porcellati, 
1983). During apoptosis, a cell’s phospholipid asymmetry is changed by translocation of 
PEs and PSs to the outer leaflet where the PSs function as recognition tags for removal by 
phagocytes (Fadok et al., 1992, De Simone et al., 2003). This causes a disruption of 
glycerophospholipid asymmetry resulting in a looser glycerophospholipid packing in the 
outer leaflet, thus allowing calcium entry. This may lead to neuronal degeneration by the 
activation of caspases and PLA2 resulting in apoptotic cell death (Farooqui et al., 2004). 




 In neural membranes, transition metal ions initiate lipid peroxidation by 
generating peroxyl and alkoxyl radicals. Due to the reactivity of the vinyl ether linkage of 
plasmalogens with singlet oxygen and other reactive oxygen species (ROS), they may act 
as antioxidants to protect biological structures against free radical attack (Sindelar et al., 
1999, Farooqui and Horrocks, 2001b).  
 




Figure 1.4 Structure of sphingolipid backbone and headgroups Modified from Merrill, 
2008. 
 
 Sphingolipids (e.g. sphingomyelins (SMs), ceramides (Cers), cerebrosides, 
sulfatides (SLs)) are also highly concentrated in nervous tissues and they are formed from 
a sphingoid backbone (sphingosine) to which fatty acids are attached via an amide bond 
(Figure 1.4) (Merrill, 2008). The headgroup at the primary hydroxyl may vary, resulting 
in the formation of different classes of sphingolipids (e.g. simple hydrogen (Cers); 
phosphocholine group (SMs); sugar residues (cerebrosides); sulfated cerebrosides (SLs)) 
(Merrill, 2008). 
 












 Phosphate (Sphingosine 1-Phosphate, S1P; 
Ceramide 1-Phosphate, Cer1P)
 Fatty acid (1-O-Acyl-Ceramide)
 Phosphocholine (Sphingomyelin)
 Other (P-inositol, P-ethanolamine)
 Glucose (and higher glycan derivatives)
 Galactose (and higher glycan derivatives)




1.2.2.2. Biosynthesis of sphingolipids 
 
Figure 1.5 Biosynthesis of sphingolipids Modified from Colombaioni and 
Garcia-Gril, 2004a. 
  
 Sphingolipid synthesis begins with the substrates palmitoyl-CoA and serine 
forming ketosphinganine via a reaction catalyzed by serine palmitoyltransferase (SPT) 
(Merrill, 2008). Next, ketosphinganine is reduced to form sphinganine via 


































ketosphinganine reductase (Merrill, 2008). Sphinganine is subsequently acylated to form 
dihydroceramide by a family of Cer synthases (Merrill, 2008). Lastly, dihydroceramide 
will then be desaturated to form Cer by dihydroceramide desaturase (Merrill, 2008). The 
Cer formed serves as a branchpoint in which other more complex sphingolipids are 
generated (Figure 1.5). SMs can be formed from Cers via the addition of a 
phosphocholine group (transferred from PCs), thereby releasing DAGs, linking the 
glycerophospholipids and sphingolipids synthesis pathways (Merrill, 2008). Alternatively, 
Cers may be glycosylated (addition of a sugar group) by glucosylceramide synthase or 
galactosylceramide (GAL-3) synthase to form cerebrosides. SLs are formed from the 
addition of a sulfate group to cerebrosides via a sulfate donor, 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) (Merrill, 2008).   
 
1.2.2.3. Catabolism of sphingolipids 
 Catabolism of sphingolipids allows the reversion of these complexes to Cers.  
Hydrolysis of SMs to Cers and phosphocholines is catalyzed by sphingomyelinase 
(Merrill, 2008). Cerebrosides are Cers with a sugar residue (glucose / galactose) at the 1-
hydroxyl moiety; hence, its hydrolysis involves the enzymes glucosidases and / or 
galactosidases to remove the sugar moiety and regenerate Cers. SLs are sulfated 
cerebrosides and its breakdown involves removal of the sulfate group catalyzed by the 
enzyme arylsulfatase (ARS) to form cerebrosides which can be further broken down to 
form Cers. Cers can subsequently be hydrolyzed to free sphingoid bases and FFAs by the 
action of ceramidases (Merrill, 2008). 
 




1.2.2.4. Role of sphingolipids 
 Sphingolipids are located in the outer leaflet of the plasma membrane bilayer, 
whilst glycerophospholipids such as PEs and PSs occur only in the inner leaflet 
(Porcellati, 1983). Similar to glycerophospholipids, sphingolipids function as structural 
components of cell membrane. Sphingolipids, together with cholesterol and certain 
categories of proteins tend to cluster together forming 'rafts' of membranes (Merrill, 
2008). As sphingolipids usually contain highly saturated alkyl chains, they are less fluid 
and have tighter packing, resulting in higher melting temperatures as compared to 
membrane glycerophospholipids. This differential packing results in phase separation, 
forming ‘liquid-ordered' sphingolipid-rich and ‘liquid-disordered' glycerophospholipid-
rich regions (Simons and Ikonen, 1997, Merrill, 2008).   
 Lipid rafts also play important roles in signal transduction. Signaling proteins 
such as epidermal growth factor receptor, insulin receptor, G proteins, nitric oxide 
synthase, and TNF-α receptor can be found within the lipid rafts (Smart et al., 1999). In 
addition, the effect of lipid rafts on neurotransmitter signaling has been implicated in 
many neurological and psychiatric diseases. Sphingolipids themselves are also signaling 
molecules involved in the control of cellular processes such as proliferation, growth, 
migration, differentiation, senescence, and apoptosis (Kolesnick and Kronke, 1998, 
Spiegel et al., 1998, Hannun and Luberto, 2000, Cuvillier, 2002, Hannun and Obeid, 
2002, Malisan and Testi, 2002). Sphingolipids can function as first messengers binding to 
G protein-coupled receptors, or as intracellular second messengers, interacting with other 
targets (Colombaioni and Garcia-Gil, 2004a). In addition, sphingolipid metabolites 
generated in cells are capable of modifying the activity of a number of proteins, including 




receptors, ion channels and enzymes, as well as intracellular calcium levels (Colombaioni 
and Garcia-Gil, 2004b).  
 
1.3. General introduction to brain PLA2 enzymes 
1.3.1. Introduction 
 The release of DHA, AA or other fatty acids are catalyzed by PLA2 enzymes, 
which specifically hydrolyze the acyl ester bond at the sn-2 position of membrane 
glycerophospholipids to produce FFAs and lysoglycerophospholipids (Dennis, 1994). In 
brain tissues, PLA2 isoforms perform housekeeping as well as signaling functions. They 
are involved in both normal maintenance of lipid homeostasis as well as in cases of 
pathological conditions, such as ischemia. PLA2 enzymes are subdivided into several 
groups depending on their structure, enzyme properties, subcellular localization, and 
cellular function. These groups include sPLA2, cPLA2, iPLA2, and plasmalogen-selective 
phospholipase A2 (PlsEtn-selective PLA2) (Farooqui et al., 1997b). Each class of PLA2 is 
further subdivided into various isozymes (Dennis, 1994).  
 
1.3.2. Types of PLA2 enzymes in brain tissues 
1.3.2.1. sPLA2 
   sPLA2, as the name suggests, is synthesized intracellularly, but secreted 
extracellulary for its actions on glycerophospholipids (Farooqui and Horrocks, 2007). 11 
members of the sPLA2 family have been identified in mammals, which are numbered and 
grouped in the order of their discovery: sPLA2IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, -X, 
-XIIA and –XIIB, have been identified in mammalian tissues (Kudo and Murakami, 




2002). These sPLA2s are characterized by their low molecular mass (12-18 kDa) and 
require only millimolar concentrations of calcium for hydrolysis of the sn-2 ester bond of 
glycerophospholipids, with overall no preference for any particular fatty acid side chains 
(Murakami and Kudo, 2002, Schaloske and Dennis, 2006, Burke and Dennis, 2009). 
Different subclasses of sPLA2 have differing expression in various regions of the brain 
and they play different roles in the nervous system.  
 sPLA2 has also been demonstrated to be involved in inflammatory conditions. The 
onset of acute inflammation involves expression and stimulation of iPLA2, with 
comparatively lower levels of sPLA2 and cPLA2 (Gilroy et al., 2004, Farooqui and 
Horrocks, 2007). However, during the resolution of inflammation, sPLA2 (types IIA and 
V) and cPLA2 were the predominant isoforms expressed (Gilroy et al., 2004). 
 
1.3.2.2. cPLA2 
 cPLA2, also known as the type IV family, consists of six intracellular enzymes, 
cPLA2α, cPLA2β, cPLA2γ, cPLA2δ, cPLA2ε and cPLA2ζ, with cPLA2α, cPLA2β, cPLA2γ 
found particularly in brain tissues (Molloy et al., 1998, Pickard et al., 1999a, Balboa et al., 
2002). They have a high molecular weight (85 – 110 kDa) and do not use calcium for 
catalysis, although submicromolar calcium concentrations are required for required for 
translocation of the enzyme from the cytosol to internal membranes, where it is 
subsequently activated by phosphorylation before hydrolysis of membrane 
glycerophospholipids (Farooqui et al., 2000b, Murakami and Kudo, 2002). Much 
research has focused on cPLA2α because of its central role in triggering the release of AA 
and eicosanoids in inflammation. Basal levels of cPLA2α mRNA are very low in neuronal 




and glial cells (Owada et al., 1994, Ong et al., 2010) and it is predominantly found in 
astrocytes of gray matter (Farooqui et al., 2000b). cPLA2β is found mainly in the 
cerebellum whilst cPLA2γ is predominantly expressed in the brain, heart, and skeletal 
muscle in humans (Pickard et al., 1999b, Ong et al., 2010).  
 cPLA2 has been implicated in various cellular responses such as differentiation, 
inflammation, mitogenesis and cytotoxicity, depending on the type of tissues or cells 
involved (Leslie, 1997). It maintains lipid homeostasis by facilitating phospholipid 
remodeling and they have a preference for AA over other unsaturated fatty acids in 
phospholipid substrates (Clark et al., 1995, Balsinde et al., 2006). In response to pro-
inflammatory factors, hydrolysis of AA-containing phospholipids generates a major pool 
of free AA which can be further oxidized to eicosanoids that play important roles in 
inducing and maintaining inflammatory responses (Farooqui and Horrocks, 2007).  In 
addition, the induction of LTP in the dentate gyrus of rats is triggered by calcium entry, 
resulting in the activation of cPLA2 and liberation of AA from neural membrane 
glycerophospholipids, especially PCs (Clements et al., 1991). 
 
1.3.2.3. iPLA2 
 iPLA2 is a 80 – 88 kDa cytosolic protein that utilizes a serine to catalyze the 
hydrolysis of the sn-2 ester bond and does not require calcium for its activity (Murakami 
and Kudo, 2002, Farooqui and Horrocks, 2007). Expression studies have indicated the 
occurrence of iPLA2α, iPLA2β and iPLA2γ (also known as group VIA-1, group VIA-2 and 
group VIB respectively) in brain tissues (Molloy et al., 1998, Zanassi et al., 1998, Balboa 
et al., 2002). Significantly higher expression of iPLA2 in all parts of the brain was 




observed as compared to cPLA2 (Farooqui et al., 1999, Ong et al., 2010). These results 
are in agreement with the findings of immunohistochemical studies showing dense iPLA2 
staining in the cortex, hippocampus and striatum (Ong et al., 2005b) and low levels of 
cPLA2 immunoreactivity observed in the cerebral neocortex, hippocampus, striatum and 
most other parts of the forebrain (Ong et al., 2010).  
 iPLA2s, like all other PLA2s, are responsible for the regulation of membrane lipid 
homeostasis. They also play important roles in intracellular signal transduction, 
neurotransmitter release and LTP (Winstead et al., 2000, Farooqui and Horrocks, 2007). 
Treatment of hippocampal slices with bromoenol lactone (BEL), a specific inhibitor of 
iPLA2, prevents the induction of LTP (Wolf et al., 1995). iPLA2 is important in synaptic 
plasticity via its importance in neurite outgrowth, neuronal differentiation and regulation 
of  hippocampal α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) 
receptors. In fact, cortical neurons showed loss of neurites and nuclear regression after 
iPLA2 inhibition with BEL (Kurusu et al., 2008). In addition, hippocampal injection of 
BEL resulted in the attenuation of short-term and long-term memory in inhibitory 
avoidance learning (Schaeffer and Gattaz, 2005). The first phase of AA release in 
inflammation involves the expression and stimulation of iPLA2, with the generation of 
eicosanoids which further propagate the inflammatory process (Gilroy et al., 2004). Other 
PLA2 enzymes, such as sPLA2 and cPLA2, have comparatively lower levels at first and 
they
 
come into play during the resolution phase (Gilroy et al., 2004).  
 Another important role of iPLA2 is its ability to release of DHA from brain 
glycerophospholipids (Strokin et al., 2003, 2007, Green et al., 2008). This was evidenced 
from studies using BEL (Strokin et al., 2003) and more specifically, the inhibition of 




group VIB iPLA2 by small interfering RNA (Strokin et al., 2007). Both studies inhibited 
DHA but not AA release from phospholipids of astrocytes stimulated with adenosine 
triphosphate (ATP) (Strokin et al., 2003, 2007). DHA released can be further metabolized 
to form docosanoids, which have neuroprotective and neurotrophic properties after 
ischemic-reperfusion injury (Marcheselli et al., 2003). They are also involved in cell 
survival and the resolution of inflammation (Lukiw et al., 2005, Schwab et al., 2007). 
Several studies demonstrated that DHA-enriched diets provide protection from lipid 
peroxidation (Strokin et al., 2006). The neuroprotective role of DHA derivatives suggests 
that iPLA2 would serve as a possible mediator in the prevention of ischemic damage 
(Strokin et al., 2006).  
 
1.3.2.4. PlsEtn-selective PLA2 
 PlsEtn-PLA2 from brain tissues has a molecular mass of 39 kDa and does not 
require calcium for its action (Farooqui and Horrocks, 2001a). This enzyme preferentially 
hydrolyzes AA and DHA from the sn-2 position of plasmalogens via a receptor-mediated 
processs, releasing lysoplasmalogens and FFAs (Farooqui and Horrocks, 2001b). The 
rate of release of DHA from labeled plasmalogen is 3-5 times faster than AA (Ong et al., 
2010). Especially high content of DHA is observed in plasmalogens (Strokin et al., 2004). 
Up to 70% of plasmalogens in neuronal membranes contain DHA at the sn-2 position, 
thereby making it an abundant endogenous source of free DHA (Farooqui and Horrocks, 
2001a). The co-localization of PlsEtn-selective PLA2 and glial fibrillary acidic protein 
(GFAP) suggests that this class of PLA2 is predominantly associated with astrocytes 




(Farooqui and Horrocks, 2001b). This is in contrast to cPLA2 and iPLA2, which are 
mainly present in neurons.  
 PlsEtn-PLA2 has also been associated with Alzheimer’s disease (AD), in which 
neurons undergo severe oxidative stress. Ethanolamine plasmalogens are decreased in 
affected regions of brain in AD and this may be due to stimulation of PlsEtn-PLA2 which 
causes excess release of AA and accumulation of eicosanoids and lipid peroxides in AD 
(Farooqui et al., 1997a). Accumulation of such lipid metabolites may contribute to 
neurodegeneration via calcium influx and further stimulation of other PLA2 enzymes 
resulting in a vicious cycle of damage to neurons (Farooqui et al., 1997a). Furthermore, 
the generation of lysoplasmalogens can induce changes in membrane permeability and 
fluidity and allow the influx of calcium, enabling the translocation of calcium-dependent 
enzymes, such as cPLA2. 
 
1.3.3. Involvement of PLA2 enzymes in neurological disorders 
 Stroke is the cessation of blow flow to the brain and disruption of metabolic 
demand with resultant stimulation of PLA2 enzymes. Stimulation of these enzymes cause 
a massive release of FFAs in brain, known as the Bazan effect (Bazan, 1970). In the early 
phase of ischemic injury, FFA accumulation is attributed to activation of cPLA2. cPLA2 
mediated hydrolysis of glycerophospholipids alters membrane permeability allowing 
more calcium to enter (Farooqui et al., 1997b, Ong et al., 2010). This subsequently 
activates sPLA2, promoting the generation of high levels of AA-derived eicosanoids and 
free radicals that induce neural cell injury and death (Farooqui et al., 1997b, Ong et al., 
2010). In immature rat brains following hypoxic ischemia, neuronal death in CA1 region 




of the hippocampus showed an increase in COX-2 and cPLA2 immunoreactivity, 
indicating that ischemic injury was associated with COX-2 and cPLA2. 
 AD represents a human brain model for inflammation with progressive 
neurodegeneration involving ROS (Bazan et al., 2002). Glycerophospholipids and 
plasmalogens in particular are good substrates for lipid peroxidation (Farooqui et al., 
1997a). This process can provide a steady supply of free radicals such as alkyl and 
peroxyl radicals, which attack cellular components such as lipids, proteins and DNA 
(Farooqui et al., 1997a). Increased activities of cPLA2 and PlsEtn-PLA2 were found in the 
nucleus basalis and hippocampal regions of AD brains compared to age-matched controls 
(Stephenson et al., 1996, Farooqui et al., 1997a). In a gene array study, profiling of 
12,633 genes in the CA1 hippocampal area of AD patients indicated an increase in cPLA2 
and COX-2 expression, plus an upregulation of a number of apoptotic and 
proinflammatory genes (Colangelo et al., 2002).  
 Depression has also been associated with changes in PLA2. Mitochondrial 
dysfunction and abnormalities in glycerophospholipid metabolism have been implicated 
in the pathophysiology of depression (Kato et al., 1993). Depressed bipolar patients have 
significantly higher phosphomonoester levels as compared to control subjects, indicating 
an accelerated glycerophospholipid metabolism in these individuals (Kato et al., 1992, 
1993). Studies in humans indicate that MDD is accompanied by an immune response 
with increased production of proinflammatory cytokines (Hulbert et al., 2005, Maes, 
2008). These cytokines may in turn induce the enhancement of glycerophospholipids 
metabolism through the activation of PLA2 (Maes, 2008). 
 




1.4. General introduction to brain omega-3 fatty acids 
1.4.1. Introduction 
Brain lipids contain a high proportion of PUFAs (Figure 1.6) derived from the 
essential fatty acid precursors, linoleic acid (LA;18:2) and α-linolenic acid (ALA; 18:3) 
which must be supplied from the diet because they cannot be synthesized by the body 
(Logan, 2003). LA and ALA can be converted to PUFAs by elongase and desaturase 
enzymes (Hulbert et al., 2005).  LA is converted to AA (20:4), the principal omega-6 
fatty acid as well as a precursor for the proinflammatory series of eicosanoids, and ALA 
undergoes elongation to produce EPA (20:5), which is further elongated to produce DHA 
(22:6), both omega-3 fatty acids (Kim, 2007, Farooqui, 2009a). However, only low levels 
of EPA are found in neural membranes (Farooqui, 2009a). DHA formed is transported by 
plasma lipoproteins through the bloodstream and some of it crosses the blood-brain 
barrier and subsequently gets esterified to membrane glycerophospholipids in the sn-2 
position of the glycerol backbone (Glomset, 2006). Among neural cells, the ability to 
synthesize DHA is seen only in astrocytes (Moore et al., 1991). Although majority of 
DHA is accumulated in neuronal membranes, the neurons themselves cannot produce 
DHA due to a lack of desaturase activity (Glomset, 2006, Kim, 2007). 
 





Figure 1.6 Chemical structures of PUFAs in the brain Adapted from 
Farooqui, 2009a.  
  
 Aside from synthesis from their dietary precursors, DHA and EPA can also be 
obtained directly from the diet. Humans have a limited capacity for the conversion of 
ALA to EPA and DHA, hence pre-formed dietary sources of EPA and DHA are the best 
ways to ensure adequate intake. This makes the dietary PUFA content of great 
importance in influencing membrane composition and consequently, membrane function 
and metabolism. DHA in particular, is the most abundant PUFA in the brain and it is 
particularly enriched in glycerophospholipids such as PEs, PSs, PCs and ethanolamine 
plasmalogens (Kim, 2007, Farooqui, 2009a). Up to 50% of the total amount of 
unsaturated fatty acids esterified to the sn-2 position of glycerophospholipids is DHA 
(Garcia et al., 1998). Studies done in synaptosomal membranes found that DHA was the 
principal esterified PUFA in PEs, PSs and ethanolamine plasmalogens (Breckenridge et 
al., 1972, Sun and Sun, 1972). As it can be seen from the structure of DHA and EPA, 




they are highly unsaturated (DHA contains 6 carbon-carbon double bonds and EPA 
contains 5 carbon-carbon double bonds), hence this unsaturation reduces the packing 
space between lipids in which they are esterified to, thereby imparting fluidity to the 
membrane.  
 
1.4.2. Release of DHA from brain glycerophospholipids 
 Plasmalogen glycerophospholipids are a special type of phospholipid with a vinyl 
ether linkage at the sn-1 position of the glycerol backbone. They often contain AA or 
DHA at the sn-2 position of the glycerol backbone. The release of DHA from 
plasmalogens is a receptor-mediated process brought about by PlsEtn-selective PLA2, 
releasing lysoplasmalogens and the FFA, DHA (Farooqui, 2009a). Lysoplasmalogens are 
usually reacylated back to form plasmalogens or hydrolyzed by lysoplasmalogenase 
(Farooqui and Horrocks, 2001a). The co-localization of PlsEtn-selective PLA2 and GFAP 
suggests that this class of PLA2 is predominantly associated with astrocytes (Farooqui 
and Horrocks, 2001b). Therefore, since astrocytes are the neuronal cell type involved in 
the biosynthesis of DHA in the brain and PlsEtn-selective PLA2 has been shown to be 
able to release DHA from rat brain astrocytes (Farooqui and Horrocks, 2001b), it further 
confirms the role of PlsEtn-selective PLA2 in the release of DHA from 
glycerophospholipids. 
Aside from ethanolamine plasmalogens, DHA can also be released from 
glycerophospholipids via iPLA2. A study demonstrated that acute release of DHA from 
stimulated astrocytes is mediated by iPLA2 (Strokin et al., 2003, 2007).  In addition, rat 
pups which were fed with omega-3 deficient diet were found to have prolonged half lives 
of DHA in the brain, thereby slowing the loss of DHA and conserving their levels 




(DeMar et al., 2004). Subsequently, it was found that the activity, protein, and mRNA of 
cPLA2 and sPLA2 were upregulated in the frontal cortex of rats consuming the omega-3 
PUFA-deprived diet, whilst only the iPLA2 isoform was downregulated. This study 
suggests that omega-3 PUFA deprivation increases the half-life of brain DHA by 
downregulating iPLA2 (Rao et al., 2007a).  
 
1.4.3. Roles of DHA in the brain 
1.4.3.1. DHA and physiochemical properties of membranes 
 Due to their highly fluidizing properties, DHA as well as EPA are found in 
highest concentrations in dynamic membranes, such as the retina, brain and spermatozoa. 
Incorporation of DHA into sn-2 side chains of glycerophospholipids contributes to the 
properties of cellular membranes, including the regulation of membrane fluidity, phase 
transition temperature, acyl chain packing (Salem et al., 1986). Unlike saturated 
phospholipid membranes where the acyl chains have tighter packing, DHA-containing 
membranes have distorted packing induced by steric restrictions of the multiple double 
bonds, making the membrane more fluid (Stillwell and Wassall, 2003). These properties 
in turn affect the activities of membrane embedded compounds such as receptors, ion 
channels, G proteins and so on (Yehuda, 2003).  
 
1.4.3.2. DHA and child brain and retinal development 
In fetal brain development, DHA is absolutely required. The membranes of 
neurons that are forming need to be fluid, therefore, making the presence of DHA an 
ideal choice. Neurons are continually forming axons and dendritic extensions with 




surrounding neurons. These synapses, which are important communicating junctions 
between neurons, are preferentially enriched in DHA (Kidd, 2007).  Oral DHA is able to 
promote the synthesis of synaptic membranes (Wurtman et al., 2006). DHA  increases the 
numbers of dendritic spines (Sakamoto et al., 2007), and probably synapses, on 
hippocampal neurons, particularly on excitatory glutamatergic synapses, thereby crucial 
for the induction and maintenance of LTP. 
Infants also require dietary DHA for retinal development and normal visual 
function (Kidd, 2007, Farooqui, 2009a). It is a major constituent of photoreceptor 
membranes, accumulating in the rod outer segment and playing an important role in 
disordering disk membranes and regulating activity of retinal enzymes (Jeffrey et al., 
2001, Farooqui, 2009a). Intake of DHA was correlated with significantly better visual 
resolution acuity at ages two months and four months (SanGiovanni et al., 2000). In 
addition, maturation of visual acuity was accelerated in infants fed with baby food 
containing DHA-enriched egg yolk (Hoffman et al., 2004). Conversely, infant rhesus 
monkeys which were deprived of DHA during prenatal and postnatal development had  
reduced visual acuity compared with control infants (Neuringer et al., 1984). 
 
1.4.3.3. DHA and learning 
 DHA is crucial for the induction and maintenance of LTP and this can be 
attenuated by iPLA2 inhibitors in rat hippocampal slices (Fujita et al., 2001). Therefore, 
the iPLA2 activation and consequent DHA release in the hippocampus may be an 
important factor for both synaptic plasticity and learning and memory (Salem et al., 
1986). In aged adults, low levels of DHA in plasma PCs are correlated with the risk of 




developing dementia, as showed by subjects enrolled in the Framingham Heart Study 
(Schaefer et al., 2006). Conversely, high intakes of omega-3-rich foods or supplements 
provided a protective mechanism against the impairment of cognitive function in middle-
aged subjected studied (Kalmijn et al., 2004). DHA also affects synaptic transmission by 
increasing the number of dendritic spines on postsynaptic neurons cells and of specific 
pre- or post-synaptic proteins in animal models (Wurtman et al., 2006, Cansev and 
Wurtman, 2007, Sakamoto et al., 2007, Cansev et al., 2008, Wurtman et al., 2009). This 
increase in spine density is not seen with AA, a PUFA of the omega-6 fatty acid class 
(Cansev and Wurtman, 2007). 
 
1.4.3.4. DHA and neuroprotection 
 DHA can be oxidatively metabolized by 15-LOX-like enzymes to form 
docosatrienes, resolvins and protectins, collective known as docosanoids, which are novel 
anti-inflammatory mediators that antagonize the effects of proinflammatory eicosanoids 
formed from AA (Hong et al., 2003, Bazan, 2009b, Farooqui, 2009a). These metabolites 
of DHA have anti-inflammatory, antithrombotic, antiarrhythmic and neuroprotective 
effects (Schwab and Serhan, 2006, Bazan, 2009b). Deficiency of DHA is associated with 
cognitive decline as mentioned previously, and this is linked to the development of AD. 
Of the protectins, neuroprotectin D1 (NPD1) has been shown to suppress amyloid-beta 
(Aβ) neurotoxicity in AD by inducing antiapoptotic gene expression (Lukiw et al., 2005, 
Bazan, 2009b). NPD1 upregulates anti-apoptotic Bcl-2 proteins, Bcl-2 and Bcl-xl, and 
decreases the expression of the pro-apoptotic proteins, Bad and Bax (Mukherjee et al., 
2004, Bazan, 2009a). Low levels of NPD1 were detected in AD brains in the 




hippocampal cornu ammonis region 1, but not in other areas of the brain (Lukiw et al., 
2005).  
In cases of ischemic reperfusion injury, the DHA pool increases due to the 
hydrolysis of glycerophospholipids by PLA2, which subsequently generates NPD1 
(Marcheselli et al., 2003, Bazan, 2009b). NPD1 is able to inhibit leukocyte infiltration 
and pro-inflammatory signaling in mice stroke models, thereby providing neuroprotective 
effects (Marcheselli et al., 2003). DHA-albumin complex infused intravenously after 
induced ischemia in rats remarkably reduced subcortical infraction and accumulated 
levels of NPD1 were detected in the ipsilateral side of the brain (Belayev et al., 2005). 
Additionally, DHA induces BDNF protein expression in rat cortical astrocytes (Rao et al., 
2007b). This may be one of the possible pathway in which DHA plays a role in 
neuroprotection, anti-apoptotic effects as well as the relief of depression. 
 
1.4.4. Importance of DHA in depression 
1.4.4.1. Status of DHA in depression 
 The levels of dietary omega-3 PUFAs are of great importance. Large scale 
population studies have shown that frequent fish consumption containing substantial 
amounts of omega-3 PUFAs is associated with decreased risk of depression (Hibbeln, 
1998). A positive correlation was found between plasma omega-3 levels and 
cerebrospinal fluid 5HIAA. Low levels of DHA predicted low levels of 5HIAA, the 
major metabolite of 5-HT, which is known to be protective against depression (Hibbeln et 
al., 1998). These authors suggested that depletion of DHA induces a change in membrane 
physical properties, which, in turn, influences the function of either 5-HT receptors or 5-




HT reuptake systems. A correlation between total seafood consumption and the 
prevalence of postpartum depression has also been established (Hibbeln, 2002). Higher 
concentrations of DHA in mother’s milk and greater seafood consumption both predicted 
lower prevalence of postpartum depression (Hibbeln, 2002).  
 It is hypothesized that a low omega-3 PUFA status could predispose subjects to 
an increased risk of suicide and depression (Tiemeier et al., 2003). Animal models 
suggest that the composition of PUFAs in red blood cell membranes may be used as an 
indicator of its composition in cerebral membranes (Logan, 2003). While not identical, 
significant correlations exist between blood and brain phospholipids (Horrobin, 2001). 
Plasma and red blood cell concentration of omega-3 fatty acids in depressed patients, 
especially DHA, have been unusually low, whilst the concentrations of AA (omega-6 
fatty acid) have been relatively high (Peet et al., 1998, Maes et al., 1999). This imbalance 
of the omega-6 / omega-3 PUFA ratio in depression is accompanied by increased levels 
of formation of eicosanoids and production of proinflammatory cytokines that would be 
detrimental to human brain function (Maes et al., 1996, Hulbert et al., 2005), whereas 
omega-3 PUFAs decrease production of these eicosanoids (Calder, 2001, Simopoulos, 
2002) Furthermore, it was shown that the administration of the inflammatory cytokine, 
alpha-interferon, to human subjects induces psychiatric symptoms similar to those found 
in MDD (Maes and Smith, 1998, Bonaccorso et al., 2001).  
 In animal research, feeding female rats with omega-3 deficient diet produced pups 
which had reduced levels of cerebral NE and exhibit decreased learning ability as 
evidenced by the active avoidance test (Takeuchi et al., 2002). This behavior can be 
rapidly reversed by supplementation of DHA after weaning (Takeuchi et al., 2002). Other 




studies have also shown widespread reductions in DHA levels observed after an omega-3 
deficient diet, and the reductions are particularly pronounced in the frontal cortex (Carrie 
et al., 2000, Rao et al., 2007b). At the same time, omega-3 PUFA deficiency in rats led to 
reduced expression of BDNF in the frontal cortex and the addition of DHA to cultured rat 
cortical astrocytes induced BDNF protein expression (Rao et al., 2007b). These 
observations ascertain that deficiency in omega-3 fatty acids during critical periods of 
neurodevelopment may result in neurological deficits and put subjects at higher risk for 
psychiatric disorders such as depression and anxiety.  
 Till date, most human / animal studies have looked at how antidepressants and 
omega-3 separately linked to depression or improved symptoms of depression. Few 
explored the possibility of antidepressants affecting omega-3 levels and subsequently 
linking to neurobiological changes in depression. One such study which aimed at finding 
out whether antidepressants and long-chain omega-3 fatty acids are mediated by common 
or divergent mechanisms, yielded negative results (McNamara et al., 2010). The 
researchers concluded that the antidepressant, fluoxetine, did not augment DHA 
biosynthesis and DHA levels in erythrocytes (McNamara et al., 2010). Limitations of this 
study were the fact that only one antidepressant was used and this would not be sufficient 
to make a generalization. In addition, fluoxetine treatments were able to reduce 5-HT 
turnover (Unceta et al., 2007, McNamara et al., 2010), whilst chronic omega-3 fatty acid 
deficiency increased 5-HT turnover (McNamara et al., 2009a). This suggested that 
antidepressants and omega-3 fatty acids do have an unknown common effect on 5-HT 
neurotransmission. 
 




1.4.4.2. Omega-3 supplementation in depression 
 In accordance to the link between omega-3 PUFA deficiency and depression, 
many double-blind randomized controlled trials have shown that supplementation with 
omega-3 PUFAs was superior to placebo in the treatment of unipolar depression (Su et al., 
2003, Nemets et al., 2006, Lin and Su, 2007). Usage of omega-3 PUFA supplements as 
augmentation therapy alongside antidepressant medications have also shown benefits 
(Nemets et al., 2002, Peet and Horrobin, 2002). In pregnant women with depression, 
pharmacotherapy is a clinical dilemma with no antidepressants approved for use in 
pregnant women by the FDA thus far due to the associated risks (Su et al., 2008). Hence, 
omega-3 PUFA supplements, being nutritional compounds with established health 
benefits, serve as safe alternatives to antidepressants. Pregnant women treated with 
omega-3 PUFAs have shown significant reductions in depression scores following 
treatment (Su et al., 2008). 
 However, there are also studies which have reported negative results (Marangell 
et al., 2003, Grenyer et al., 2007). Therefore, it remains to be proven if omega-3 PUFA 
supplements do have a role in depression therapy, and if so, the suitable dosage, duration 
and ratio of DHA / EPA content need to be determined. 










Chapter II Study aims 




 Depression is a common and symptoms can affects all aspects of a person's life, 
causing much distress. Varying treatments for depression include antidepressants, ECT, 
rTMS and omega-3 supplementation. A correlation between the intake of omega-3 
PUFAs and the prevalence of depression has been shown in many studies carried out by 
investigators throughout the world (Hibbeln, 1998, De Vriese et al., 2004, Astorg et al., 
2008, Su et al., 2008). This provides an interesting link between antidepressants and lipid 
mediators in depression, which has not been widely studied. Many antidepressants are 
able to interact with the lipid bilayer (Herbette et al., 1986, Seydel et al., 1994, Fisar et al., 
2004), yet it is still vague with regards to how these antidepressants affect lipids in 
different regions of the brain, at the individual molecular species level.  
 Indeed, this unknown area reflects the aim of this study, in which lipid profiles in 
the brain were examined after various modalities of antidepressant treatment. From these 
preliminary results, trends in lipid changes were identified and subsequent investigations 
carried out. We proposed that perhaps changes in lipid profiles take place after different 
modalities of antidepressant treatments, namely, antidepressant drugs and rTMS, thereby 
supporting the evidence for a common downstream effect amongst various treatment 
modalities of depression, including omega-3 PUFA supplementation. 
 The first study makes use of a few commonly used antidepressants to analyse 
lipid profiles. Results from lipidomic analyses showed a drop in phospholipids with a 
corresponding increase in lysophospholipids, hence postulating the presence of enhanced 
PLA2 enzyme activity. The next study involves the use of an antisense to iPLA2, along 
with an animal behavioural model of depression and lipidomics to investigate the role of 




iPLA2. It was found that iPLA2 was indeed essential in the reduction of stress-related 
behavioral despair brought about by maprotiline, an antidepressant studied. iPLA2 
antisense was also able to reverse the lipid changes induced by maprotiline. Finally, the 
last part of the study uses rTMS, which has been shown to be useful in the management 
of depression (O'Reardon et al., 2007, Avery et al., 2008, Bloch et al., 2008, Fitzgerald, 
2008, George et al., 2010). Once again, we made used of lipidomics to examine changes 
in lipid profiles after rTMS and it was found to be similar to that observed after 
antidepressant treatments. 


































Chapter 3.1. Lipidomic analyses of the mouse brain after 
antidepressant treatment 





Low levels of omega-3 PUFA (DHA and EPA) intake may be associated with 
depression and alterations in 5-HT function (Hibbeln, 1998, Peet et al., 1998, Mischoulon 
and Fava, 2000, Logan, 2003, Su et al., 2003, Logan, 2004, Su et al., 2008). Seasonal (De 
Vriese et al., 2004) and geographic (Hibbeln, 1998) variations in intake of omega-3 
PUFAs are also linked to the incidence of depression. Conversely, intake of high levels of 
omega-3 fatty PUFAs have been reported to have an antidepressant effect (Mischoulon 
and Fava, 2000, Logan, 2003, Su et al., 2003, Logan, 2004, Su et al., 2008). The balance 
between omega-3 and omega-6 PUFAs allows neural cell membranes to develop with 
exactly the right flexibility and fluidity, to carry messages among neurons and glial cells 
(Caramia, 2008). Plasma and red blood cell concentrations of omega-3 PUFAs in 
depressed patients, especially DHA, have been unusually low, whilst the concentrations 
of AA (omega-6 PUFA) have been relatively high (Peet et al., 1998, Maes et al., 1999). 
This imbalance of the omega-6 / omega-3 PUFA ratio in depression is accompanied by 
increased levels of formation of eicosanoids and production of proinflammatory 
cytokines that would be detrimental to human brain function (Maes et al., 1996, Hulbert 
et al., 2005), whereas omega-3 PUFAs would decrease production of these eicosanoids 
(Calder, 2001, Simopoulos, 2002). Recently, there has been considerable interest in a 
possible link between changes in brain PUFAs, neural membrane phospholipid 
degradation, 5-HT neurotransmission, and depression (Maes et al., 1999). It is proposed 
that some of these processes may be involved in the action of antidepressant drugs (Fisar 
et al., 2005).  




Many antidepressants are cationic amphiphilic drugs that interact with the lipid 
bilayer (Herbette et al., 1986, Seydel et al., 1994, Fisar et al., 2004) . High affinity 
binding of TCAs to PCs or PEs have been demonstrated (Fisar, 2005). PCs and PEs are 
two of the most abundant phospholipid classes and they play an important role in 
maintaining membrane integrity as well as regulating downstream signal transduction 
pathways (Fisk and Kano-Sueoka, 1992, Exton, 1994). Thus far, however, little is known 
about the effects of antidepressants on lipids in different regions of the brain, at the 
individual molecular species level. 
Lipidomics is a systems-level analyses and characterization of lipids and their 
interacting moieties (Wenk, 2005, Adibhatla et al., 2006). Tandem mass spectrometry 
analyses (MS/MS) together with multiple reaction monitoring (MRM) is used for 
quantitative analyses of lipids with known fragmentation profiles with up-front liquid 
chromatography (Watson, 2006). In view of the above-mentioned studies showing lipid 
changes in depressed subjects / animals, as well as after antidepressant treatment, we 
hypothesize that specific lipid species might be altered after chronic antidepressant 
treatment. The present study aims to examine changes in lipid profiles in various regions 
of the mouse brain through lipidomics, using three different antidepressants of two main 
pharmacological classes, maprotiline (SNRI), fluoxetine (SSRI), and paroxetine (SSRI). 
 
3.1.2. Materials and methods 
3.1.2.1. Antidepressant treatment and collection of brain tissues 
16 male Balb/C mice weighing between 20-30 g each and about 6-8 weeks old 
were used for this study. The mice were divided into four groups, each comprising of 




four mice, and given daily intraperitoneal (i.p.) injections of maprotiline, fluoxetine or 
paroxetine (Sigma-Aldrich Co., St. Louis, MO, USA, 10 mg/kg in saline) or saline for 
four weeks. They were housed under defined conditions (room temperature 22°C, relative 
humidity 65%, lighting 12 hours/day) with free access to food and water. The dose of 10 
mg/kg of was chosen based on previous studies which showed behavioral changes in 
animal models (Parra et al., 2000, Reneric et al., 2001, Shirayama et al., 2002, Pinhasov 
et al., 2005) as well as neurochemical changes (Laakso et al., 1996, Martinez-Turrillas et 
al., 2002, Tan et al., 2006, Alme et al., 2007) after antidepressant administration. This 
duration is also sufficient for antidepressants to exert their therapeutic effects in relation 
to adaptive cellular changes (Fisar, 2005). The mice were sacrificed after four weeks of 
treatment. They were deeply anesthetized by i.p. injection of ketamine / xylazine cocktail, 
followed by decapitation. The left and right PFC, hippocampus, striatum and cerebellum 
were rapidly collected, snap frozen in liquid nitrogen and stored at - 80°C until analyses. 
All procedures involving animals were approved by the Institutional Animal Care and 
Use Committee of the National University of Singapore, and in accordance with the 
guidelines of the National Advisory Committee for Laboratory Animal Research. 
 
3.1.2.2. Lipidomic analyses 
3.1.2.2.1. Lipid extraction 
A widely used modified protocol of Bligh and Dyer was used (Bligh and Dyer, 
1959). Tissues were homogenized in 750 µl of chloroform-methanol, 1:2 (v/v) using 
Tissue Tearor™ (Biospec. Inc, Bartlesville, USA). Samples were vortexed and incubated 
on ice for 15 mins with vortexing done at every 5 mins interval. Subsequently, 250 µl of 




chloroform and 450 µl of 0.88% potassium chloride (KCl) were added. Samples were 
vortexed and incubated on ice for 1 min. Lipids were isolated from the organic phase 
after centrifugation (9000 rpm, 4°C, 2 mins). Samples were then vacuum dried (Thermo 
Savant SpeedVac, Waltham, MA), resuspended in chloroform-methanol (1:1 v/v), and 
used for analyses. 
 
3.1.2.2.2. Internal standards 
 Levels of individual lipid levels were quantified using spiked internal standards 
including C14-PC dimyristoyl PC (28:0-PC), dimyristoyl PE (28:0-PE), dimyristoyl C14-
PS (28:0-PS), dimyristoyl PG (28:0-PG), dimyristoyl PA (28:0-PA) and C19-Cer, which 
were obtained from Avanti Polar Lipids (Alabaster, AL, USA). Dioctanoyl PI (16:0-PI) 
was used for PI quantitation and obtained from Echelon Biosciences, Inc. (Salt Lake City, 
UT, USA).  
 
3.1.2.2.3. Analyses of lipids using high performance liquid chromatography (HPLC) / 
mass spectrometry  
An Agilent HPLC system coupled with an Applied Biosystem Triple 
Quadrupole/Ion Trap mass spectrometer (4000Qtrap, Foster City, California, USA) was 
used for quantification of individual polar lipids. Samples were introduced into the mass 
spectrometer by loop injections with chloroform:methanol (1:1) as a mobile phase for 
positive electrospray ionisation (ESI) mode and chloroform:methanol:200 mM piperidine 
(1:1:0.1) as a mobile phase for negative ESI mode, respectively, both at a flow of 250 
uL.min
-1
 (Shui et al., 2007). Based on product ion and precursor ion analyses of head 




groups, two comprehensive sets of MRM transitions were set up for quantitative analyses 
of various lipids including PCs, PEs, PSs, PIs, PGs, PAs, SMs and Cers (Fei et al., 2008). 
The signal intensity of each MRM value was normalized using Equation (1). The data 
were tested for normality using SPSS statistical software version 16.0 and looking at the 
Shapiro-Wilk significance value. The data were shown to be normally distributed. 
Comparisons of the means of various lipids were performed for the control and treatment 
groups. The differences between control and treatment groups were determined 
statistically using Student’s t test (using False Discovery Rate (FDR) adjustment) with 




3.1.2.3. Real-time RT-PCR 
An additional 12 mice were used for this portion of the study. Six were injected 
with i.p. maprotiline and six were injected with i.p. saline (control) for 28 days. At the 
end of the treatment duration, they were sacrificed and the PFC quickly removed and 
immersed in RNAlater®(Ambion, TX, USA), snap frozen in liquid nitrogen and kept at  -
80ºC till analyses. Total RNA was extracted from the PFC using TRIzol reagent 
(Invitrogen, CA, USA) according to the manufacturer’s protocol. RNeasy® MiniKit 
(Qiagen, Inc., CA, USA) was used to purify the RNA. The samples were then reverse 
transcribed using the High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems, CA, USA). Reaction conditions were as follows: 25 
o
C for 10 mins, 37 
o
C 
for 120 mins and 85 
o
C for 5 secs. Subsequently, real-time PCR amplification was carried 
Signal intensity of lipid 1 
 Relative abundance of lipid 1  = 
 Signal intensity of all MRM transition measured 
 (1) 




out via the 7500 Realtime PCR system (Applied Biosystems, CA, USA) using TaqMan® 
Universal PCR MasterMix (Applied Biosystems, CA, USA), and sPLA2-IB (Applied 
Biosystems ID Mm00478249_m1), sPLA2-IIA (Mm00448160_m1), sPLA2-IIC 
(Mm00476915_m1), sPLA2-X (Mm00449530_m1), cPLA2α (Mm00447040_m1), iPLA2 
(Mm00479527_m1) or beta-actin probes were utilized according to the manufacturers’ 
instructions. Beta-actin was used as an internal control and all primers and probes were 
synthesized by Applied Biosystems. The PCR conditions were: an initial incubation of 50 
o
C for 2 mins and 95 
o
C for 10 mins followed by 40 cycles of 95 
o
C for 15 secs and 60 
o
C 
for 1 min. All reactions were carried out in triplicates. The threshold cycle, CT, which 
correlates inversely with the levels of target mRNA, was measured as the number of 
cycles at which the reporter fluorescence emission exceeds the preset threshold level. The 
amplified transcripts were quantified using the comparative CT method as described 
previously (Livak and Schmittgen, 2001) with the formula for relative fold change = 2
-
∆∆CT
. The mean was calculated and possible significant differences between the PFC of 
maprotiline-treated and control samples were analyzed using the Student’s t-test. P < 0.05 
was considered significant.  
 
3.1.3. Results 
3.1.3.1. Raw data heat plots of lipid changes after antidepressant treatment 
Overall changes in relative abundances of most lipid species analyzed in various 
brain regions are displayed as heat plots using their normalized intensity. These heat plots 
give us an overview of the changes across all individual lipid species. Raw data heat plots 
showed that there were no gross perturbations in lipids in the various brain regions (PFC, 




hippocampus, striatum and cerebellum) analysed after antidepressant treatments (Figures 
3.1 and 3.2).  
 






Figure 3.1 Raw data heat plots showing changes in relative abundance of lipids in the 
PFC (A) and hippocampus (B) after antidepressant treatment. Asterisks indicate 
Figure 1.
A B Hippocampus





































































































































































































































































































































significant difference compared to saline treated mice (FDR < 0.05 by Student’s t test 











Figure 3.2 Raw data heat plots showing changes in relative abundance of lipids in the 
striatum (A) and cerebellum (B) after antidepressant treatment. No significant changes 


























































































































































































































































































3.1.3.2. Ratio heat plots of lipid changes after antidepressant treatment 
 In comparison, ratio heat plots (where the relative abundance of saline is fixed as 
a value of 1) showed clearer changes in lipids, even for those species with lower relative 
abundances in the brain samples (Figures 3.3 and 3.4). 






Figure 3.3 Ratio heat plots showing changes in relative abundance of lipids in the PFC 
(A) and hippocampus (B) after antidepressant treatment. Asterisks indicate significant 


































































































































































































































































































































Figure 3.4 Ratio heat plots showing changes in relative abundance of lipids in the 
striatum (A) and cerebellum (B) after antidepressant treatment. No significant changes 




















































































































































































































































































3.1.3.3. Lipids changes in the PFC after antidepressant treatment  
 A summary of the changes in relative abundance of selected lipid species after 
various antidepressant treatments are shown in Table 3.1 below. The effects of each 
individual antidepressant on lipids will be elaborated further in the following sections. 
Lipid species 
Relative abundance ( x10
-3
) after saline or antidepressant treatments 
Saline Maprotiline Fluoxetine Paroxetine 
Phosphatidylcholines     
PC32:0 194.39±9.67 219.13±4.18* 211.20±9.25 226.86±9.83* 
PC36:1 83.65±7.35 68.40±4.04* 71.81±7.48 63.84±2.27* 
PC38:3 8.07±0.26 6.59±0.38* 7.16±0.63 5.98±0.19* 
PC40:2p 0.16±0.01 0.11±0.00* 0.13±0.04 0.10±0.00* 
PC40:6 24.57±1.17 19.53±0.50* 22.71±2.34 20.69±0.41* 
PC40:5 3.48±0.15 2.38±0.16* 2.91±0.64 1.87±0.07* 
PC42:7p 1.98±0.32 0.62±0.03* 1.31±0.83 0.59±0.09* 
PC42:6p 5.73±0.64 0.46±0.03* 3.40±2.97 0.54±0.06* 
PC42:5p 2.32±0.29 0.35±0.05* 1.48±1.21 0.32±0.01* 
Lysophosphatidylcholines     
LysoPC16:0 1.85±0.05 3.70±0.17* 2.38±0.89 2.46±0.12* 
LysoPC18:2 0.19±0.02 0.53±0.03* 0.36±0.16 0.44±0.04* 
LysoPC18:0 1.02±0.06 1.76±0.07* 1.17±0.32 1.24±0.08* 
Phosphatidylethanolamines     
PE36p:4 8.29±1.61 5.05±0.71* 7.35±1.59 4.41±1.16* 
PE36:5 0.67±0.12 0.32±0.03* 0.38±0.14 0.29±0.13* 
Sphingomyelins     
SM18/16:0 1.72±0.09 2.28±0.16* 1.90±0.15 1.98±0.13 
SM18/24:1 7.00±0.90 4.89±0.46* 5.02±1.27 4.56±0.50* 
SM18/24:0 3.42±0.41 2.43±0.21* 2.41±0.62 2.34±0.27* 
Ceramides     
Cer d18:1/18:0 0.93±0.06 1.93±0.15* 1.52±0.74 1.80±0.13* 
Cer d18:1/20:0 0.05±0.01 0.10±0.01* 0.09±0.03 0.10±0.01* 
Cer d18:1/22:0 0.04±0.01 0.08±0.01* 0.06±0.02 0.07±0.01* 
Cer d18:1/24:0 0.04±0.01 0.06±0.01* 0.06±0.01 0.05±0.01 
 
Table 3.1 Changes in relative abundance of lipids in the PFC after antidepressant 
treatment. Asterisks indicate significant difference compared to saline treated mice 
(*, FDR < 0.05 by Student’s t test with FDR adjustment). 
 
3.1.3.3.1. Maprotiline  
 There was a significant reduction in relative abundance of PC species (PC36:1, 
PC38:3, PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p, PC42:5p) and significant 
increase in relative abundance of PC32:0 in the cortex of the maprotiline treated mice as 




compared to controls (Table 3.1, Figure 3.5A, Figure 3.5B). The significant drop in 
relative abundance was observed in majority of PCs with longer carbon chain length. In 
contrast to the decrease in PCs, an increase in relative abundance of 
lysophosphatidylcholine (lysoPC) species lysoPC16:0, lysoPC18:2 and lysoPC18:0 were 
detected after maprotiline treatment (Table 3.1, Figure 3.5C).  
 
 
Figure 3.5 Graphs showing changes in relative abundance of selected PCs (A 
and B) and lysoPCs (C) in the PFC after maprotiline. Asterisks indicate 
significant difference compared to saline treated mice (*, FDR < 0.05 by 
Student’s t test with FDR adjustment). 
 




PE species PE36p:4 and PE36:5 were decreased after treatment (Table 3.1). SM 
species SM18/16:0 was increased, whilst SM18/24:1 and SM18/24:0 were decreased 
after treatment (Table 3.1). Cer species Cer d18:1/18:0, Cer d18:1/20:0, Cer d18:1/22:0 
and Cer d18:1/24:0 showed significant increase after treatment (Table 3.1).  
 
3.1.3.3.2. Fluoxetine  
There was a non-significant trend to a reduction in relative abundance of PCs in 
the cortex of mice treated with fluoxetine. A non-significant trend to an increase in 
relative abundance of lysoPCs was also detected. 
 
3.1.3.3.3. Paroxetine  
There was a significant reduction in relative abundance of PC36:1, PC38:3, 
PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p, PC42:5p (Table 3.1, Figure 3.6A and B) 
and significant increase in relative abundance of PC32:0 in the cortex of paroxetine 
treated mice, compared to controls. In contrast to the decrease in PCs, an increase in 
relative abundance of lysoPC species including lysoPC16:0, lysoPC18:2 and lysoPC18:0 
(Table 3.1, Figure 3.6C) were detected after treatment.  




Figure 3.6 Graphs showing changes in relative abundance of selected PCs (A 
and B) and lysoPCs (C) in the PFC after paroxetine. Asterisks indicate 
significant difference compared to saline treated mice (*, FDR < 0.05 by 
Student’s t test with FDR adjustment). 
 
PE36p:4, PE36:5, SM18/24:1 and SM18/24:0 showed significant decrease, whilst 
Cer species, Cer d18:1/18:0, Cer d18:1/20:0, Cer d18:1/22:0 and Cer d18:1/24:1 showed 
significant increase after treatment (Table 3.1).  
 




3.1.3.4. Lipids changes in the hippocampus after antidepressant treatment 
Changes in relative abundance of selected lipid species after various 
antidepressant treatments are summarized in Table 3.2. There were no significant 
changes in any of the lipids analyzed in the hippocampus of mice treated with 
antidepressants. 
Lipid species 
Relative abundance ( x10
-3
) after saline or antidepressant treatments 
Saline Maprotiline Fluoxetine Paroxetine 
Phosphatidylcholines     
PC32:0 169.63±10.19 171.68±2.05 176.60±4.48 179.82±5.55 
PC36:1 103.00±11.09 101.40±3.69 102.01±6.82 104.10±1.71 
PC38:3 9.84±0.53 10.01±0.25 10.08±0.38 9.27±0.29 
PC40:2p 0.188±0.03 0.20±0.01 0.29±0.13 0.18±0.01 
PC40:6 21.48±2.19 19.93±0.50 18.78±0.65 19.32±1.09 
PC40:5 3.93±0.43 3.54±0.04 3.51±0.10 3.14±0.12 
PC42:7p 1.99±0.40 2.13±0.10 2.12±0.33 2.55±0.08 
PC42:6p 2.91±0.14 3.39±0.16 2.96±0.16 3.73±0.25 
PC42:5p 1.11±0.09 1.32±0.09 1.47±0.10 1.71±0.16 
Lysophosphatidylcholines     
LysoPC16:0 2.23±0.10 2.13±0.10 2.13±0.21 1.51±0.16 
LysoPC18:2 0.07±0.00 0.06±0.01 0.13±0.08 0.05±0.01 
LysoPC18:0 1.34±0.14 1.24±0.04 1.39±0.30 1.04±0.12 
Phosphatidylethanolamines     
PE36p:4 0.74±0.27 0.55±0.11 0.67±0.22 0.38±0.01 
PE36:5 0.07±0.03 0.08±0.02 0.07±0.02 0.04±0.03 
Sphingomyelins     
SM18/16:0 1.83±0.21 1.67±0.05 2.45±0.93 2.04±0.07 
SM18/24:1 8.77±1.69 8.40±0.26 9.26±1.80 8.90±0.56 
SM18/24:0 4.54±1.06 4.24±0.26 5.77±2.14 5.16±0.28 
Ceramides     
Cer d18:1/18:0 0.56±0.06 0.55±0.04 0.71±0.05 0.53±0.03 
Cer d18:1/20:0 0.05±0.01 0.04±0.01 0.04±0.00 0.03±0.01 
Cer d18:1/22:0 0.03±0.00 0.02±0.00 0.03±0.01 0.03±0.00 
Cer d18:1/24:0 0.03±0.01 0.04±0.00 0.04±0.02 0.04±0.01 
 
Table 3.2 Changes in relative abundance of lipids in the hippocampus after 
antidepressant treatment. Asterisks indicate significant difference compared to 
saline treated mice (*, FDR < 0.05 by Student’s t test with FDR adjustment). 
 
3.1.3.5. Lipids changes in the striatum after antidepressant treatment 
Changes in relative abundance of selected lipid species after various 
antidepressant treatments are summarized in Table 3.3. There were no significant 
changes in any of the lipids analyzed in the striatum of mice treated with antidepressants. 





Relative abundance ( x10
-3
) after saline or antidepressant treatments 
Saline Maprotiline Fluoxetine Paroxetine 
Phosphatidylcholines     
PC32:0 96.84±4.66 102.11±5.50 110.53±4.40 93.50 ±6.24 
PC36:1 75.81±5.36 82.73±6.49 77.70±4.53 84.09±9.79 
PC38:3 9.06±0.38 9.40±0.96 9.21±0.23 9.50±0.25 
PC40:2p 0.22±0.04 0.28±0.06 0.25±0.05 0.29±0.09 
PC40:6 23.04±1.64 22.20±0.65 22.82±0.48 22.07±1.67 
PC40:5 4.50±0.65 4.18±0.44 4.46±0.11 4.50±0.13 
PC42:7p 21.41±0.60 20.35±0.22 19.37±0.74 19.96±0.17 
PC42:6p 100.13±5.46 96.85±2.89 95.86±0.70 99.35±2.11 
PC42:5p 40.48±2.80 37.50±0.33 36.33±0.30 39.36±1.49 
Lysophosphatidylcholines     
LysoPC16:0 0.96±0.18 0.79±0.05 0.66±0.04 0.80±0.11 
LysoPC18:2 0.04±0.01 0.03±0.01 0.03±0.00 0.03±0.02 
LysoPC18:0 0.57±0.08 0.56±0.08 0.46±0.02 0.55±0.08 
Phosphatidylethanolamines     
PE36p:4 18.33±5.24 19.10±4.45 20.80 ±1.05 21.25±2.09 
PE36:5 1.18±0.07 1.07±0.05 1.11±0.05 1.06±0.06 
Sphingomyelins     
SM18/16:0 0.46±0.08 0.62±0.05 0.56±0.03 0.56±0.07 
SM18/24:1 7.04±1.01 8.10±1.09 7.06±0.72 8.07±1.81 
SM18/24:0 5.95±0.88 6.82±0.89 5.91±0.46 6.81±1.15 
Ceramides     
Cer d18:1/18:0 0.26±0.07 0.24±0.02 0.25±0.04 0.25±0.06 
Cer d18:1/20:0 0.02±0.01 0.02±0.01 0.01±0.00 0.02±0.01 
Cer d18:1/22:0 0.02±0.01 0.03±0.01 0.01±0.00 0.01±0.01 
Cer d18:1/24:0 0.06±0.01 0.08±0.02 0.08±0.01 0.07±0.02 
 
Table 3.3 Changes in relative abundance of lipids in the striatum after 
antidepressant treatment. Asterisk indicates significant difference compared to 
saline treated mice (*, FDR < 0.05 by Student’s t test with FDR adjustment). 
 
3.1.3.6. Lipids changes in the cerebellum after antidepressant treatment  
Changes in relative abundance of selected lipid species after various 
antidepressant treatments are summarized in Table 3.4. There were no significant 
changes in any of the lipids analyzed in the cerebellum of mice treated with 
antidepressants. 
Lipid species 
Relative abundance ( x10
-3
) after saline or antidepressant treatments 
Saline Maprotiline Fluoxetine Paroxetine 
Phosphatidylcholines     
PC32:0 103.82±3.29 105.99±5.29 111.39±2.29 104.30±7.56 
PC36:1 92.52±2.41 99.14±3.21 91.82±1.80 98.31±1.89 
PC38:3 7.47±0.25 7.59±0.40 7.20±0.17 7.59±0.20 




PC40:2p 0.25±0.03 0.23±0.02 0.26±0.03 0.30±0.09 
PC40:6 44.96±1.07 42.81±3.77 41.26±0.70 41.84±3.57 
PC40:5 2.91±0.24 2.89±.0.11 2.63±0.19 2.84±0.15 
PC42:7p 22.11±1.44 21.51±1.74 22.55±1.23 22.85±1.39 
PC42:6p 84.72±1.20 81.75±1.45 82.78±1.66 82.06±1.44 
PC42:5p 36.05±1.65 35.27±1.68 36.16±1.00 34.26±0.68 
Lysophosphatidylcholines     
LysoPC16:0 0.64±0.09 0.66±0.07 0.66±0.10 0.60±0.13 
LysoPC18:2 0.05±0.01 0.07±0.02 0.038±0.00 0.06±0.02 
LysoPC18:0 0.44±0.06 0.51±0.08 0.40±0.04 0.43±0.03 
Phosphatidylethanolamines     
PE36p:4 7.06±0.19 6.14±0.37 7.24±0.65 6.61±0.59 
PE36:5 1.10±0.02 1.01±0.07 1.07±0.06 1.05±0.09 
Sphingomyelins     
SM18/16:0 0.97±0.04 1.08±0.07 1.09±0.08 1.06±0.06 
SM18/24:1 8.50±0.44 9.75±0.91 8.22±0.14 9.92±1.12 
SM18/24:0 8.99±0.31 9.89±0.93 8.96±0.17 10.25±1.14 
Ceramides     
Cer d18:1/18:0 0.17±0.05 0.17±0.05 0.16±0.06 0.15±0.02 
Cer d18:1/20:0 0.01±0.00 0.02±0.01 0.01±0.01 0.02±0.01 
Cer d18:1/22:0 0.02±0.00 0.03±0.01 0.02±0.01 0.02±0.02 
Cer d18:1/24:0 0.09±0.01 0.10±0.01 0.11±0.03 0.11±0.01 
 
Table 3.4 Changes in relative abundance of lipids in the cerebellum after 
antidepressant treatment. Asterisk indicates significant difference compared to 
saline treated mice (*, FDR < 0.05 by Student’s t test with FDR adjustment). 
 
 
3.1.3.7. Real-time RT-PCR analyses of PLA2 enzymes after maprotiline treatment 
 No significant differences in mRNA expression of the various PLA2 enzymes 
were detected after maprotiline treatment (Figure 3.7). In addition, relative expression of 
the PLA2 enzymes showed that iPLA2 was the most abundant enzyme in the PFC of 
control mice, followed by cPLA2 (Figure 3.8). sPLA2-IB expression was low; sPLA2-IIA 
and sPLA2-IIC expression were slightly higher; and sPLA2-X was expressed at extremely 
low levels such that it could not be detected on this scale. Expression patterns were 
similar for maprotiline-treated mice (data not shown).  






Figure 3.7 Real-time RT-PCR analyses of differentially expressed PLA2 
enzymes in the mice PFC after maprotiline treatment. Data were analyzed by 
Student’s t-test. No significant difference in relative fold change was observed. 
 
Figure 3.8 Real-time RT-PCR analyses of relative expression of PLA2 enzymes in the 
mice PFC after saline treatment.The values were normalized to the lowest level of 
message amongst the enzymes, i.e., the value for sPLA2-IB, to give an indication of 
relative expression of the various PLA2 enzymes in the PFC. The values were normalized 
to the lowest level of message amongst the enzymes, i.e., the value for sPLA2-IB, to give 
an indication of relative expression of the various PLA2 enzymes in the PFC. Data 









 The present study was carried out to elucidate possible effects of NRI and SSRI 
antidepressant drugs on brain lipid profiles. Decreases in PC species PC36:1, PC38:3, 
PC40:2p, PC40:6, PC40:5, PC42:7p, PC42:6p andPC42:5p were detected in the PFC 
after treatment with two out of the three antidepressants (maprotiline and paroxetine). 
Fluoxetine showed similar trends in the cortex as the other two antidepressants used, 
although the results were not statistically significant. The striatum exhibited a general 
reduction in PE species, although the results were not statistically significant. The 
findings are in general agreement with that of a previous study, which showed reductions 
in PE in rat brain plasma membranes by thin layer chromatography (Fisar et al., 2005). 
 The decrease in phospholipid species in the PFC is accompanied by increases in 
lysophospholipid species in the same brain region. These include increases in lysoPC16:0, 
lysoPC18:2 and lysoPC18:0 in the PFC after treatment with maprotiline and paroxetine. 
No significant changes in lipid profiles were observed in the striatum, hippocampus and 
cerebellum in comparison to the PFC. LysoPCs are able to exert their effects by affecting 
membrane permeability and fluidity along with a variety of biological effects (Farooqui 
et al., 1997b). They also participate in many signal transduction processes; modulate ion 
channel permeability, cell-cell and membrane-membrane interactions and 
neurotransmitter release (Farooqui et al., 2008). 
 PCs and PEs are one of the major phospholipids found distributed in membrane 
bilayers (Devaux, 1991).The decrease in phospholipids and increase in the corresponding 
lysophospholipids in the PFC suggest the action of PLA2 activity after antidepressant 




treatment. PLA2 is a lipolytic enzyme that hydrolyzes the acyl group at the sn-2 position 
of membrane phospholipids to produce FFAs and lysophospholipids (Farooqui and 
Horrocks, 2004). Based on the decrease in PC species (PC36.1, PC38:3, PC40:2p, 
PC40:6, PC40:5, PC42:7p, PC42:6p and PC42:5p) and corresponding increases in 
lysophospholipid species, i.e. lysoPC16:0, lysoPC18:2 and lysoPC18:0 in the PFC of the 
antidepressant-treated mice, the identity of the fatty acid side chain being released can be 
deduced. For instance, PC40:6 - lysoPC18:0 = 22:6 (DHA); PC40:5 – lysoPC18:0 = 22:5 
(docosapentaenoic acid (DPA)) In addition to DHA, it is possible that even longer chain 
fatty acids, such as tetracosapentaenoic acid (24:5, e.g. PC42:5p - lysoPC18:0 or PC40:5 
- lysoPC 16:0) or tetracosahexaenoic acid (nisinic acid) (24:6) may also be released 
through the action of antidepressants. Of the three antidepressants tested, only fluoxetine 
did not exhibit any significant changes. This result is supported by recent preclinical 
findings which show no increase in omega-3 PUFA biosynthesis or membrane 
composition after chronic fluoxetine treatment in rats (McNamara et al., 2010). The same 
study, however, did show significantly increased levels of DPA in the PFC of female rats 
(McNamara et al., 2010). In addition, amongst the three antidepressants used, fluoxetine 
has the lowest propensity to inhibit NET. Paroxetine, on the other hand, has 
anticholinergic and weak NRI properties (Hyttel, 1994, Stahl, 2008, Sghendo and Mifsud, 
2012). It is possible that this similarity in pharmacologic profile could have contributed to 
the similar lipid changes as maprotiline (NRI and anticholinergic properties as well). 
 Very little is known about the molecular mechanisms associated with 
antidepressants used in this study. Aside from increasing 5-HT levels, fluoxetine also 
blocks 5-HT2C receptors (which have inhibitory effect on NE and DA release via gamma 




amino-butyric acid (GABA) interneurons), thereby enhancing its therapeutic effects (Ni 
and Miledi, 1997, Stahl, 2008). It is reported that fluoxetine treatment results in an 
increase in cPLA2 enzyme protein levels and activity in the rat brain (Rao et al., 2006). In 
vitro studies showed that 5-HT1 receptors are coupled via G proteins to PLA2 activation 
(Axelrod, 1990, Felder et al., 1990, Qu et al., 2003). Fluoxetine-mediated release of 
various PUFAs from neural membrane phospholipids in depressive states may not only 
modulate gene expression for COX, LOX and protein kinase C, but also control activities 
of transcription factors (Jump, 2004). The results obtained in this study were in contrast 
to the study mentioned above (Rao et al., 2006) which showed an increase in cPLA2 
enzyme protein levels and activity in the rat brain after fluoxetine treatment. cPLA2 is 
specific for phospholipids containing AA in the side chain (Farooqui and Horrocks, 
2004). By deduction, the findings did not show any increase in the release of omega-6 
fatty acids such as AA (20:4). Hence, the results suggested that there might be other 
isoforms of PLA2 involved here.  
 Data from real-time RT-PCR analyses showed no significant changes in 
expression of any of the PLA2 enzymes investigated, hence showing that there were no 
changes in levels of mRNA transcripts. iPLA2 showed a non-significant increase in fold 
change by around 1.5 times. It is possible that there might be increased PLA2 activity 
without an increase in expression levels. Subsequently, the relative expression of various 
PLA2 enzymes in the PFC of both control and maprotiline-treated mice were analysed. 
iPLA2 was the most abundant enzyme in the PFC, followed by cPLA2. The abundance of 
iPLA2 over other PLA2 enzymes was also observed in rats and monkey brains (Ong et al., 
2005a, Ong et al., 2010). 




  Omega-3 and omega-6 PUFAs are major structural components of neuronal and 
glial cell membranes, and changes in levels of PUFAs may modulate lipid/lipid raft 
composition, a process that affects G-protein receptor-mediated monoamine signaling 
(Tyeryar et al., 2008). This signaling may promote synaptic plasticity, neurogenesis, and 
adaptation associated with action of antidepressants (Warner-Schmidt and Duman, 2006). 
An important role of iPLA2 is its selective preference for DHA side chains in the sn-2 
position of brain glycerophospholipids (Strokin et al., 2003, 2007, Green et al., 2008). In 
addition, PlsEtn-selective PLA2 may also have a role to play in the generation of FFAs 
since it acts on the sn-2 position of ethanolamine and choline plasmalogens (e.g.PC42:5p) 
to produce DHA (Farooqui and Horrocks, 2001a). 
 It can be concluded that antidepressant treatment results in changes in 
phospholipid composition and possible endogenous release of long-chain PUFAs, 
including omega-3 fatty acids such as DHA. It is postulated that the endogenous release 
of long-chain fatty acids may be related to the mechanism of action of the antidepressants. 
The changes in PCs and lysoPCs mentioned above were found after treatment with 
maprotiline and paroxetine. Fluoxetine showed similar trends to maprotiline and 
paroxetine, however, the changes were not statistically significant. These lipid changes 
did not appear to be due to differences in main pharmacological actions of the 
antidepressants used. This was evidenced by similar lipid changes in maprotiline and 
paroxetine which exert their antidepressant effect via different mechanisms of action. 
From the results, it was noted that the findings were regionally selective for the PFC in 
particular. Further studies would be necessary to investigate the relationship between 
antidepressants and PLA2 enzymes in the PFC, in particular, iPLA2. In addition, the non-




statistically significant results produced by fluoxetine, which is one of the most widely 
used antidepressant should be looked at in depth, for instance, by varying the dose of 
fluoxetine. 
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There is an increasing interest in the pathophysiology and neurochemistry of the 
PFC during depression. Abnormalities in activity of the PFC have been reported in 
depression, in excess of other brain regions (Davidson et al., 2002). Depressed subjects 
have overall reduced perfusion / metabolism in the PFC (Drevets et al., 2002, Kimbrell et 
al., 2002), with distinct hypoactivity in the (DLPFC and hyperactivity in the VMPFC 
(Mayberg, 1994, Drevets, 1998). Moreover, postmortem studies showed reduction in 
PFC volume (Drevets, 2000, Botteron et al., 2002) in the brains from subjects with 
depression with decreased density of neurons and glia in the DLPFC and orbital PFC 
(Ongur et al., 1998, Rajkowska et al., 1999). 
Changes in long chain fatty acids are associated with depression. Plasma and red 
blood cells concentrations of omega-3 fatty acids, especially DHA, are unusually low in 
depressed patients, whilst the concentrations of AA (an omega-6 fatty acid) are relatively 
high (Peet et al., 1998, Maes et al., 1999). Imbalance of the omega-6 / omega-3 PUFA 
ratio in depression is accompanied by increased formation of proinflammatory 
metabolites of AA or eicosanoids (Hulbert et al., 2005). Such an increased ratio has been  
often reported in serum levels or post mortem studies of depressed patients (Maes et al., 
1996, Conklin et al., 2007, Kiecolt-Glaser et al., 2007), although some studies reported a 
decreased ratio (McNamara et al., 2009b). Intake of high levels of omega-3 fatty acids is 
reported to have an antidepressant effect (Mischoulon and Fava, 2000, Logan, 2004, Su 
et al., 2008). Reduced levels of DHA and neurotrophic factor, BDNF, are observed in the 
Chapter 3.2. Lipidomic and behavioral analyses on the role of iPLA2 in the antidepressant 




frontal cortex of rats fed with an omega-3 deficient diet (Carrie et al., 2000, Rao et al., 
2007b). 
Serum levels of DHA have a profound influence on brain DHA metabolism. Low 
DHA levels in the diet and serum resulted in decreased activity of iPLA2 (Rao et al., 
2007a). The latter is highly expressed in the cerebral cortex, hippocampus and striatum 
(Ong et al., 2010); (Ong et al., 2005b), and it is important for the endogenous release of 
DHA from phospholipids (Strokin et al., 2003, 2007, Green et al., 2008). iPLA2β 
knockout mice show widespread and significant baseline reductions in incorporation 
coefficients k* and rates Jin of DHA (Basselin et al., 2010). DHA by itself, or through its 
metabolites, docosanoids, may have an important role in supporting the function of 
neurons (Mukherjee et al., 2004, Bazan, 2009a) 
The previous study of the mouse brain after antidepressant treatment using the 
technique of lipidomics, which is a systems-level analyses and characterization of lipids 
and their interacting moieties (Wenk, 2005, Adibhatla et al., 2006), showed a possible 
link between antidepressant treatment with two different classes of antidepressants, 
maprotiline and paroxetine, and the endogenous release of long chain PUFAs in the PFC 
(Lee et al., 2009). Due to the large sample size required for different treatment groups, 
only one antidepressant was selected for this study. Maprotiline was chosen based on the 
significant changes in lipids in the previous study. This present study aims to elucidate a 
possible role of iPLA2 present in the PFC in the antidepressant effect of maprotiline. It is 
shown that cortical iPLA2 is essential in the antidepressant effect of maprotiline, and is 
strongly associated with its ability to endogenously release DHA from 
glycerophospholipids.  
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3.2.2. Materials and methods 
 
 
Figure 3.9 Schematic flowchart of the experimental outline and animal 
groupings 
 
3.2.2.1. Western blot to show knockdown of iPLA2 
Nine Balb/C mice were used for this portion of the study to demonstrate the 
effectiveness of iPLA2 antisense oligonucleotide treatment. The animals were randomly 
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divided into three groups (three mice in each group) and injected with i.c. saline, sense or 
antisense oligonucleotide as described below. The mice were sacrificed after one week by 
deep anaesthesia and decapitation, and the pooled left and right PFC was dissected out. It 
was subsequently homogenized in 10 volumes of ice-cold lysis buffer (150 mM sodium 
chloride, 50 mM Tris–hydrochloride, 0.25 mM EDTA, 1% Triton X-100, 0.1% sodium 
orthovanadate, and 0.1% protease inhibitor cocktail, pH 7). After centrifugation at 
10,000 × g for 30 mins at 4ºC, the supernatant was collected. Protein concentrations in 
the preparation were measured using a Bio-Rad protein assay kit (Bio-Rad Laboratories, 
CA, USA). The homogenates (50 μg) were resolved in 10% SDS polyacrylamide gels 
under reducing conditions and electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane. Nonspecific binding sites on the PVDF membrane were blocked by 
incubation with 5% non-fat milk in 0.1% Tween 20 TBS (TTBS) for 1 hour. The PVDF 
membrane was then incubated overnight at 4 °C with antibody to iPLA2 (Santa Cruz, CA, 
USA) (diluted 1:500) in 1% bovine serum albumin in TTBS. After washing with TTBS, 
the membrane was incubated with horseradish peroxidase-conjugated anti-goat IgG 
(1:2,000 in TTBS, Pierce, Rockford, IL) for 1 hour at room temperature. 
Immunoreactivity was visualized using a chemiluminescent substrate (Supersignal West 
Pico, Pierce, Rockford, IL) according to manufacturer's instructions. Exposed films 
containing blots were scanned, and the densities of the bands were measured, using Gel-
Pro Analyzer 3.1 program (Media Cybernetics, Silver Spring, MD). The densities of the 
iPLA2 bands were normalized against those of beta-actin, and the mean ratios were 
calculated. Significant differences were analyzed using Student’s t-test. P < 0.05 was 
considered significant. 
Chapter 3.2. Lipidomic and behavioral analyses on the role of iPLA2 in the antidepressant 




3.2.2.2. Antidepressant treatment 
54 male Balb/C mice weighing between 20-30 g each were used for this study. 
They were housed under defined conditions (room temperature 22°C, relative humidity 
65%, lighting 12 hours/day) with free access to food and water. The mice were divided 
into two equal groups (27 mice per group), and given daily i.p. injections of maprotiline 
(Sigma-Aldrich Co., St. Louis, MO, USA, 10mg/kg in saline) or saline for a total of 28 
days. The dose of 10mg/kg of was chosen based on previous studies which showed 
behavioral changes in animal models (Parra et al., 2000) as well as neurochemical 
changes (Tan et al., 2006) after antidepressant administration. This duration is also 
sufficient for antidepressants to exert their therapeutic effects in relation to adaptive 
cellular changes (Fisar, 2005).  
At day 21 of i.p. saline / maprotiline treatment, each group was further subdivided 
into three groups of nine mice each (a total of six treatment groups). They were 
administered antisense oligonucleotide to iPLA2, scrambled sense or saline via i.c. 
injection as described in the next section and FSTs conducted one week later. Mice were 
sacrificed 24 hours after the last day of saline / maprotiline treatment. Fresh harvesting of 
tissues (for lipidomic anlyses) was carried out in five mice per treatment group. They 
were deeply anesthetized by i.p. injection of ketamine / xylazine cocktail, followed by 
decapitation. Pooled samples of the left and right PFC were rapidly dissected, snap frozen 
in liquid nitrogen and stored at - 80°C until analyses. The remaining four mice per 
treatment group were perfused for histochemical studies as described in section 3.2.2.5. 
All procedures involving animals were approved by the Institutional Animal Care and 
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Use Committee of the National University of Singapore, which is in accordance to the 
National Advisory Committee for Laboratory Animal Research guidelines. 
 
3.2.2.3. Intracortical (i.c.) injection of antisense 
At day 21 of i.p. saline / maprotiline treatment, each group was further subdivided 
into three groups of nine mice each, Mice were administered antisense oligonucleotides 
to iPLA2, scrambled sense or saline via i.c. injection. The antisense oligonucleotide used 
was a 20-base oligonucleotide corresponding to nucleotides 59-78 of the murine GroupVI 
iPLA2 sequence (5’-CTCCTTCACCCGGAATGGGT-3’). This sequence is identical to 
that which has been shown to be effective in reducing Group VI iPLA2 expression in 
mouse P388D1 macrophage-like cells (Balsinde et al., 1997). As a control, the sense 
sequence was used (5’-ACCCATTCCGGGTAAAGGAG-3’). Antisense and sense 
oligonucleotides contain phosphorothioate linkages to prevent nuclease degradation. 
Mice were deeply anesthetized by i.p. injection of ketamine / medetomidine cocktail and 
placed on a stereotaxic apparatus (Stoelting, Wood Dale, USA). Antisense 
oligonucleotide (3 μg/μl), sense oligonucleotide (3 μg/μl) or sterile saline was 
stereotaxically injected into the left and right DLPFC through small craniotomies over 5 
mins at a volume of 1 μl per side (coordinates: 2.5 mm rostral to bregma, 1.5 mm lateral 
to the midline, 1.5 mm from the surface of the cortex) (Figure 3.10) and the scalp sutured. 
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Figure 3.10 (A) Lateral and (B) cross-sectional view of the mouse brain 
showing the i.c. injection sites. Coordinates used for the were as follows: 
2.5 mm rostral to bregma, 1.5 mm lateral to the midline and 1.5 mm from 
the surface of the cortex. Modified from Paxinos and Watson, 2001. 
 
3.2.2.4. Modified FST  
 
 FSTs were carried out using a procedure modified from the original report by 
Porsolt (Porsolt et al., 1977), one week after i.c. injections were administered. Saline or 
maprotiline was administered 30 mins before conducting the test. The mice were 
individually placed into glass cylinders (25 cm height; 10 cm diameter) containing 10 cm 
of water maintained at 22–24°C for a total of 6 mins in a random order. Two mice at a 
time were videotaped from the side and an opaque cardboard divider separated the 
cylinders so that the mice could not see each other during the trials. The predominant 





Sites of intracortical injection
A
B
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behavior which each mouse exhibited was recorded every 5 secs during the last 4 mins of 
the 6-mins trial period, allowing 2 mins of acclimatization. The behaviors included were 
immobility, climbing and swimming. Swimming behavior is defined as movement 
(usually horizontal) throughout the cylinder that also includes crossing into another 
quadrant; climbing movement is defined as upward-directed movements of the forepaws 
along the side of the cylinder; immobility is defined as the absence of active, escape-
oriented behaviors such as swimming, jumping, rearing, sniffing, or diving (Detke et al., 
1995, Cryan et al., 2002). Any mouse appearing to have difficulty keeping its head above 
water was removed from the test and deleted from the study, however, no such 
incidences were recorded. After the trials, the mice were dried and placed in a cage 
surrounded by heat pad for 15-20 mins. The observer was blind to the experimental 
treatment. The differences in mean counts of activity between various treatment groups 
were determined statistically using one-way analyses of variance (ANOVA) with 
Bonferroni’s post-hoc test. P< 0.05 was considered statistically significant.  
 
3.2.2.5. TUNEL and DAPI histochemistry 
 Four mice per treatment group were perfused on Day 29. Mice were deeply 
anesthetized and perfused through the left cardiac ventricle with a solution of 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The fixed brains were removed 
and the PFC was sectioned coronally at 10 μm using a cryostat and mounted on gelatin-
coated slides. While sectioning, the slices were constantly observed using Olympus 
CX31 system microscope (Olympus Corporation, Tokyo, Japan) for evidence of slight 
tissue damage due to the injection needle, so as to determine the exact regions of i.c. 
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injection to be used for staining. Tissues slices were permeabilised with 0.1% TritonX-
100 and 0.1% sodium citrate in phosphate buffer saline (PBS) for 10 mins at room 
temperature. DNA fragmentations were then stained using an In situ Cell Death 
Detection Kit, Fluorescein (Roche Diagnostics GmbH, Mannheim, Germany) according 
to the manufacturer’s instructions. ProLong® Gold Antifade Reagent with DAPI 
(Invitrogen, CA, USA) was used as a nuclear counterstain and mounting agent. Tissue 
slices treated with DNase I (2.73 U/μl, Qiagen, USA) for 10 mins at room temperature 
were used as positive controls. The sections were examined using an Olympus BX51 
system microscope (Olympus Corporation, Tokyo, Japan). 
 
3.2.2.6. Lipidomic analyses 
3.2.2.6.1. Lipid extraction 
Lipid extraction was carried out as previously described in 3.1.2.2.1. 
 
3.2.2.6.2. Internal standards 
 Levels of individual lipid levels were quantified using spiked internal standards 
including 28:0-PC, 28:0-PE, 28:0-PS and C19-Cer, which were obtained from Avanti 
Polar Lipids (Alabaster, AL, USA). 16:0-PI was used for PI quantitation and obtained 
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3.2.2.6.3. Analyses of lipids using HPLC / mass spectrometry  
 Analyses of lipids were carried out as previously described in 3.1.2.2.3. Based on 
product ion and precursor ion analyses of head groups, two comprehensive sets of MRM 
transitions were set up for quantitative analyses of various lipids including PCs, PEs, PSs 
and PIs (Fei et al., 2008).  
 
3.2.3. Results 
3.2.3.1. Western blot analyses 
 Western blotting (Figure 3.11) demonstrated that the antisense oligonucleotide 
significantly decreased iPLA2 expression one week after i.c. injection. Hence, FST was 
conducted one week following i.c. injection. 
 
Figure 3.11 Western blot analyses of iPLA2 protein expression in the PFC of 
mice after i.c. injection with saline, sense or antisense oligonucleotides. (A) 
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actin were also assayed to verify equal loading of samples. (B) Quantification 
of Western blots. iPLA2 bands were normalized to beta-actin. Significant 
decrease in the density of detected bands was observed in antisense-injected 
mice as compared to both saline and sense-injected controls as analyzed by 
Student’s t-test. Asterisk indicates significant difference from both saline and 
sense-injected controls (*, P < 0.05).   
 
 
3.2.3.2. Effect of iPLA2 antisense oligonucleotide on apoptosis 
 
  
Figure 3.12 Detection of apoptosis after i.c. injection of antisense to iPLA2.Positive 
control (A-C). TUNEL assay (A, green); DAPI staining (B, blue); merged image of 
TUNEL and DAPI counterstaining (C, green-blue). TUNEL-positive cells were 
seen. i.p. Maprotiline + i.c. antisense (D-F). TUNEL assay (A, green); DAPI 
staining (B, blue); merged image of TUNEL and DAPI counterstaining (C, green-
blue). No apparent DNA fragmentation was detected. Scale bar, 200 μm. 
 
 Positive control sections of the PFC showed intensive TUNEL-positive staining 
of almost all the nuclei (Figures 3.12A-C). In contrast, i.p. maprotiline + i.c. antisense 
sections exhibited TUNEL-negative staining (Figures 3.12D-F). All sections from the 
other treatment groups also showed TUNEL-negative results (data not shown). This 
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showed that there was an absence of apoptosis, even after injection of iPLA2 antisense 
oligonucleotide. 
 
3.2.3.3. Modified FST 
3.2.3.3.1. Effects of maprotiline on active behaviors 
 
 Results from one-way ANOVA showed a significant effect of various treatment 
groups on immobility (F(5,47) = 14.25, p<0.001) and climbing (F(5,47) = 18.30, 
p<0.001). In contrast, swimming activity was not affected by any form of treatment 
administered (F(5,47) = 0.87, p>0.05). Mean counts of immobility of i.p. maprotiline + 
i.c. saline (21.0 + 3.1) and i.p. maprotiline+ i.c. sense (23.2 + 3.0) were significantly 
decreased when compared to all groups of i.p. saline-treated controls (Figure 3.13). This 
showed that maprotiline had an antidepressant effect by reducing the period of behavioral 
despair exhibited (as measured by immobility) when the animals were subjected to 
stressful conditions.  
 The modified FST, which uses 5 secs sampling intervals to observe the 
predominant activity in each time block allowed us to tabulate climbing and swimming 
activities, in addition to immobility. Mean counts of climbing of i.p. maprotiline + i.c. 
saline (18.6 + 1.9) and i.p. maprotiline + i.c. sense (17.7 + 3.6) were significantly 
increased as compared to all groups of i.p. saline-treated controls (Figure 3.13). Mean 
counts of swimming were not statistically significant across all treatment groups. 
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Figure 3.13 Mean counts of immobility, climbing and swimming. Top panel inset is a 
tabulation of the mean counts of activity + sd. Immobility: i.p. maprotiline + i.c. sense / 
saline injection showed significantly decreased immobility as compared to all other 
treatment groups. Climbing: i.p. maprotiline + i.c. sense / saline injection showed 
significantly increased climbing as compared to all other treatment groups. Asterisks 
indicate significant differences in mean counts of using one-way ANOVA with 
Bonferroni’s post-hoc test. (***, P< 0.001) 
  
3.2.3.3.2. Effects of iPLA2 antisense oligonucleotide on active behaviors 
 Mean counts of immobility of i.p. maprotiline + i.c. antisense (29.8 + 1.9) was 
significantly increased when compared to i.p. maprotiline + i.c. saline (21.0 + 3.1) or 
sense (23.2 + 3.0) (Figure 3.13). In addition, the increase in mean counts of immobility 
after iPLA2 antisense oligonucleotide was not significantly different as compared to all 
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Saline      Maprotiline
Swimming
Mean counts (mean + sd)
i.p. i.c. Immobility Climbing Swimming
Saline
saline 30.7 + 3.9 6.7 + 2.0 10.7 + 2.4
sense 31.4 + 1.4 8.125 + 2.8 8.5 + 2.8
antisense 30.6 + 2.0 9.1 + 2.8 8.3 + 2.8
Maprotiline
saline 21.0 + 3.1*** 18.6 + 1.9*** 8.2 + 3.1
sense 23.2 + 3.0*** 17.7 + 3.6*** 7.1 + 3.5
antisense 29.8 + 1.9 9.8 + 2.9 8.4 + 3.3
Saline      MaprotilineSaline      Maprotiline
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 Mean counts of climbing was significantly decreased in the i.p. maprotiline + i.c. 
antisense (9.8 + 2.9) group as compared to i.p. maprotiline + i.c. sense (17.7 + 3.6) or 
saline (18.6 + 1.9) (Figure 3.13). This result was once again comparable to that of all 
groups of i.p. saline controls; ie, the effect of maprotiline was abolished by the 
administration of iPLA2 antisense oligonucleotide. Mean counts of swimming were not 
statistically significant across all treatment groups. 
 All 3 activities of immobility, climbing and swimming were not significantly 
different across i.p. saline-treated controls.  
 
3.2.3.4. Lipidomic analyses after iPLA2 antisense oligonucleotide 
 
 Results from one-way ANOVA showed significant treatment effects on some of 
the lipid species analyzed (F values not shown, P<0.05). Results from bonferroni test to 
compare mean relative abundances of sample pairs will be elaborated as follows. 
 Significant increases in relative abundances of PC32:0, PC38:3 and PC38:4 were 
observed after i.p maprotiline + i.c. saline / sense treatment as compared to all other 
treatment groups (Figure 3.14). Relative abundances PC36:4 and PC38:5 were 
significantly increased after i.p maprotiline + i.c. saline / sense treatment compared to i.p. 
saline + i.c. saline (Figure 3.14B). The majority of PCs, namely, PC38:6, PC40:2p, 
PC40:6, PC40:5 and PC40:4 showed significant decreases in relative abundances after 
maprotiline + i.c. saline / sense treatment as compared to all other treatments (Figure 
3.14A and B). 
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Figure 3.14 Relative abundances of PCs in the mice PFC . Asterisks indicate 
significant differences in relative abundances of i.p maprotiline + saline / sense as 
compared to all other treatment groups using one-way ANOVA with Bonferroni’s 
post-hoc test. (*, P< 0.05). Pound signs indicate significant differences in relative 
abundances of i.p maprotiline + saline / sense as compared to i.p. saline + i.c. saline 
using one-way ANOVA with Bonferroni’s post-hoc test. (#, P< 0.05). 
 
 Significant increases in relative abundances of lysoPC16:0, lysoPC18:1 and 
lysoPC20:4 were observed after i.p maprotiline + i.c. saline / sense treatment as 
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Figure 3.15 Relative abundances of lysoPCs in the mice PFC . Asterisks indicate 
significant differences in relative abundances of i.p maprotiline + saline / sense as 
compared to all other treatment groups using one-way ANOVA with Bonferroni’s 
post-hoc test. (*, P< 0.05).  
 
 PEs showed significant decreases in relative abundances across all species after 
i.p maprotiline + i.c. saline / sense treatment as compared to all other treatment groups 
(Figure 3.16A and B). The species affected were PE38p:6, PE38p:5, PE38p:4, PE40p:7, 
PE40p:6 and PE40p:5, which were mainly from the plasmalogen class of phospholipids. 
Relative abundance of PE40p:4 after i.p maprotiline + i.c. saline treatment was decreased 
in comparison to all other treatment groups (Figure 3.16A). Lastly, relative abundance of 
PE34p:1 after i.p maprotiline + i.c. saline / sense treatment was significantly decreased 
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Figure 3.16 Relative abundances of PEs in the mice PFC . Asterisks indicate 
significant differences in relative abundances of i.p maprotiline + saline / sense as 
compared to all other treatment groups using one-way ANOVA with Bonferroni’s 
post-hoc test. (*, P< 0.05). Pound signs indicate significant differences in relative 
abundances of i.p maprotiline + saline / sense as compared to i.p. saline + i.c. 
antisense using one-way ANOVA with Bonferroni’s post-hoc test. (#, P< 0.05). 
 
 Similar to lysoPCs, relative abundances of lysoPEs (lysoPE16:0 and 
lysoPE18:1) were also significantly increased after i.p maprotiline + i.c. saline / 
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Figure 3.17 Relative abundances of lysoPEs in the mice PFC . Asterisks indicate 
significant differences in relative abundances of i.p maprotiline + saline / sense as 
compared to all other treatment groups using one-way ANOVA with Bonferroni’s 
post-hoc test. (*, P< 0.05). 
 
 No significant differences in relative abundances of lipids were observed between 
all i.p. saline-treated controls and i.p. maprotiline + i.c. antisense mice. Similarly, no 
significant differences were seen between i.p. maprotiline + i.c. saline and i.p. 
maprotiline + i.c. sense mice. 
 
3.2.4. Discussion 
This study aims to investigate the role that iPLA2 plays in the therapeutic action of 
an antidepressant, maprotiline, using FST as a behavioral screen along with lipidomic 
analyses. Maprotiline is a tetracyclic antidepressant which is selective for the NET and 
has been commonly used in the treatment of depression and research studies involving 
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antidepressant effects in drugs and it is sensitive to the effects of all major classes of 
antidepressants (Porsolt et al., 1977, Detke et al., 1995). We have made use of a modified 
FST which is more sensitive in differentiating the mechanisms of action of 
antidepressants by detecting active behaviors displayed by the mice (Cryan et al., 2002). 
The PFC region was selected for i.c. injection of antisense oligonucleotide as 
abnormalities in activity in this region have been reported more frequently than for any 
other brain region in depressed subjects (Davidson et al., 2002) 
Results from i.p. maprotiline + i.c. saline / sense oligonucleotide injections 
showed that maprotiline was an effective antidepressant by reducing the level of 
behavioral despair, as measured by immobility, in mice. This was accompanied by a 
significant increase in mean counts of climbing behavior. More importantly, it was able 
to increase mean counts of climbing activity as compared to all other treatment groups. In 
contrast, mean counts of swimming did not show any significant changes. Studies have 
shown that the modified FST is sensitive in differentiating antidepressants with 5-HT or 
NE mechanisms. Climbing activity is sensitive to drugs with selective effects on 
catecholamine transmission (Cryan and Lucki 2000; Cryan et al. 2005; Detke et al. 1995; 
Hemby et al. 1997), whilst swimming is sensitive to 5-HT compounds such as the SSRIs.  
Results obtained were in accordance with that done by other groups (Detke et al., 1995). 
The above results are in contrast to that observed in i.p. maprotiline + i.c. saline / 
antisense oligonucleotide injected mice. Administration of i.c. antisense oligonucleotide 
to i.p. maprotiline-treated mice significantly increased mean counts of immobility and 
decreased mean counts of climbing to levels comparable to saline-treated controls, 
indicating that it abolished the antidepressant effect of maprotiline. iPLA2 antisense 
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oligonucleotide alone did not have any effect on behavioral despair activities as i.p. saline 
+ i.c. antisense treatment did not result in any significant changes in mean counts of 
immobility, climbing or swimming in comparison to i.p. saline + i.c. saline / sense 
animals. TUNEL assay showed that there was no apoptotic cell death after administration 
of iPLA2 antisense oligonucleotide or tissue injury from the i.c. injection procedure itself, 
hence the results of the FST can be attributed to the effect of iPLA2 inhibition and 
maprotiline, and not, apoptosis-induced changes. Together, the results show that the 
antidepressant effect of maprotiline is closely associated with iPLA2 enzymatic activity, 
and that abolishment of enzymatic activity of iPLA2 could abrogate the antidepressant 
effect of maprotiline. 
The previous study showed significant decreases in PCs accompanied by 
increases in lysophospholipid species in the PFC after treatment with antidepressants 
maprotiline and paroxetine (Lee et al., 2009). This indicated increased PLA2 activity with 
resultant endogenous release of fatty acids such as DHA (Lee et al., 2009). Since iPLA2 is 
the class of PLA2 involved in the release of DHA from phospholipids (Strokin et al., 
2003, Rao et al., 2007a), it was hypothesized that enhanced iPLA2 activity might be 
responsible for the antidepressant effect of maprotiline. In this study, lipidomic analyses 
showed significant decreases in phospholipids (PCs and PEs, including the plasmalogen 
species) and corresponding increases in lysophospholipids (lysoPCs and lysoPEs) after 
i.p. maprotiline + saline / sense oligonucleotide treatment, indicating PLA2 activity as a 
result of antidepressant treatment. However, when i.c. antisense oligonucleotide to iPLA2 
was administered along with i.p. maprotiline, the lipid changes were reversed and relative 
abundances became comparable to that of i.p. saline-treated controls. Based on the 
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decreases in phospholipids and corresponding increases in lysophospholipid species, the 
identity of the fatty acid side chain being released can be deduced. For instance, PC38p:6 
– lysoPC16:0 = 22:6 (DHA) and PE40p:7 – lysoPE 18:1 = 22:6 (DHA). The results 
suggest increased activity of iPLA2 and perhaps, PlsEtn-PLA2, which acts on the sn-2 
position of phospholipids to produce DHA and lysophospholipids (Farooqui and 
Horrocks, 2001a). No significant changes in relative abundances of lipids after i.p. saline 
+ i.c. antisense were detected in comparison to i.p. saline + i.c. saline / sense treatments. 
The direct association of abolishment of antidepressant activity of maprotiline with 
iPLA2 inhibition, and lack of release of long chain fatty acids, including DHA, after 
inhibition of enzyme activity, strongly suggest a role of DHA in the antidepressant effect 
of maprotiline, and possibly other antidepressants which show similar release of long 
chain fatty acids in the PFC after chronic treatment in mice. These could include 
paroxetine, which belongs to a different class of antidepressant as compared to 
maprotiline.  
iPLA2 is important in synaptic plasticity via its importance in neurite outgrowth, 
neuronal differentiation and regulation of hippocampal AMPA receptors. Dietary PUFA 
deprivation in rats decreases the concentration of DHA in the frontal cortex and increases 
its half-life by decreasing the activity, protein and mRNA expression of iPLA2 in the rat 
frontal cortex (Rao et al., 2007a). Enhanced iPLA2 activity can increase DHA release 
from glycerophospholipids; whilst decrease in iPLA2 may serve to reduce the metabolic 
loss of brain DHA, thus prolonging its half-life (Rao et al., 2007a). In line with the above 
findings, the current results postulate increased endogenous DHA release with increased 
iPLA2 activity induced by maprotiline treatment. DHA release from 
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glycerophospholipids can in turn be further metabolized to form docosanoids, which may 
play a role in the relief of depressive symptoms. Of the docosanoids, NPD1 upregulates 
the anti-apoptotic proteins, and decreases the expression of the pro-apoptotic proteins, 
thereby increasing neuronal survival (Mukherjee et al., 2004, Bazan, 2009a). DHA is also 
crucial for the induction and maintenance of LTP by affecting synaptic transmission via 
increasing the number of dendritic spines on postsynaptic neurons cells and specific 
synaptic proteins in animal models (Wurtman et al., 2006, Cansev and Wurtman, 2007, 
Sakamoto et al., 2007, Cansev et al., 2008, Wurtman et al., 2009). It does so probably 
through the potentiation of N-methyl-D-aspartic acid (NMDA) receptor response 
(Nishikawa et al., 1994, Fujita et al., 2001) Thus far, however, it has not been 
investigated if docosanoids generated have an anti-depressive role. 
In conclusion, this study strongly suggests a possible role of iPLA2 in the 
mechanism of antidepressants, particularly maprotiline. It is likely that one of the 
possible mechanisms of maprotiline is the induction of iPLA2 activity which in turn 
hydrolyzes phospholipids to release DHA. The exact pathway is still unknown. It will be 
worthwhile to study this interesting link and perhaps unravel new mechanisms by which 
antidepressants exert their effects. 











Chapter 3.3. Lipidomic analyses of the rat brain after rTMS 
 





The abundance of lipids in the brain together with their roles in cellular 
membranes and formation of metabolites for signal transduction pathways underlie their 
importance in many CNS disorders. Alterations in lipid metabolism have been reported 
not only in neurodegenerative disorders such as AD and Parkinson’s disease, but also 
cerebral ischemia, epilepsy, schizophrenia and depression (Farooqui and Horrocks, 1994, 
Adibhatla and Hatcher, 2007, 2008). TMS is increasingly used in the management of 
neurologic disorders such as depression as well as chronic pain. It involves the 
application of a magnetic flux to induce secondary currents in the brain and action 
potentials in neurons, and can be used to map alterations in connectivity between cortical 
areas and / or their spinal projections (Barker et al., 1985, Kobayashi and Pascual-Leone, 
2003, Bestmann, 2008). rTMS induces enduring changes in cortical function and 
plasticity-like changes, affecting processes such as neural repair, learning and memory 
(Hallett, 2000, Kobayashi and Pascual-Leone, 2003, Bestmann, 2008). Depending on 
stimulation parameters, induced electrical currents depolarize neurons resulting in 
changes in cortical function and behavior (Ziemann, 2004) and muscle activation 
(Kapogiannis and Wassermann, 2008). High frequency rTMS stimulation (>5Hz) 
enhances motor excitability, whereas low frequency stimulation (1 Hz) depress cortical 
excitability (Rossi et al., 2000).  
The effects of rTMS are not limited to the stimulated cortex, but also involve 
other connected areas within a functional network (Koch and Rothwell, 2009, Lefaucheur, 
2009). Small-scale studies suggest that rTMS could be useful in the management of 




depression and chronic pain (Lefaucheur et al., 2006, O'Reardon et al., 2007, Avery et al., 
2008, Bloch et al., 2008, Fitzgerald, 2008, George et al., 2010). A recent meta-analyses 
concluded that patients with depression treated with high-frequency rTMS over the left 
DLPFC show improved outcomes as compared to control subjects (Schutter, 2009). In 
addition, rTMS rescued defects in LTP in rats as shown by FST, suggesting that rTMS 
treatment rescued impaired synaptic efficiency caused by depression (Kim et al., 2006). 
Increased levels of BDNF mRNA were also detected in the rat brain after rTMS, similar 
to the effects of antidepressant drug treatment (Muller et al., 2000). In addition, the same 
increase was replicated in humans with increased serum levels of BDNF shown after 
rTMS treatment (Yukimasa et al., 2006, Zanardini et al., 2006).  
Despite the importance of lipids in membrane structure and cell signaling (Jump, 
2004, Adibhatla and Hatcher, 2007) little is known about possible changes in brain lipids 
after rTMS. In this study, rTMS was carried out on rats by simulating a protocol that is 
effective for treatment of depression in human patients (Pascual-Leone et al., 1996, 
Eschweiler et al., 2000), followed by lipidomic analyses to elucidate changes in lipids at 
the individual molecular species level, in regions of the brain thought to be important in 
depression, i.e. the PFC (Drevets, 2000), hippocampus (Sapolsky, 2001) and striatum 
(Aizenstein et al., 2005). Lipidomics is a systems level analyses and involves 
characterization of lipids and their interacting moieties (Wenk, 2005, Adibhatla et al., 
2006). Tandem mass spectrometry analyses (MS/MS) together with MRM is used for 
quantitative analyses of lipids of known fragmentation profiles with up-front liquid 
chromatography (Watson, 2006). Changes in relative abundance of lipids, in particular, 
sulfated GAL-3 or SLs which are a class of lipids found in myelin and neurons (Farooqui, 




1981, Eckhardt, 2008) and plasmalogens after rTMS, might be related to the endogenous 
release of PUFAs, and beneficial effects of rTMS. 
 
3.3.2. Materials and methods 
3.3.2.1. Rats and rTMS 
 A total of 12 Male Wistar rats weighing around 200-250 g each were used in this 
study. They were housed under defined conditions (room temperature 22°C, relative 
humidity 65%, lighting 12hours/day) with free access to food and water. Rats were 
randomly divided into rTMS groups (two groups) and a sham control group consisting of 
four rats per group.  Rats were anesthetized by i.p. injection of ketamine / xylazine 
cocktail and rTMS was carried out using a Magstim® QuadroPulseTM Model 500 
stimulator (Magstim, Whitland, United Kingdom) capable of delivering a maximum 
output of 2.5 Tesla via pulses of 100 µs duration. A 7-cm diameter figure of eight coil 
was used. The center of the coil was positioned over the left cerebral hemisphere 
(Sachdev et al., 2007) with reference to an atlas (Paxinos and Watson, 1986). The handle 
of the coil was parallel to the spine of the rat, and the surface of the coil was placed just 
touching the fur and tangential to the scalp, but not pressing on the skull. Rats were 
administered with either 50 pulses of TMS at 30% intensity (30% of the maximum output 
of the stimulator) or 200 pulses of TMS at 100% intensity per day for five consecutive 
days. Each pulse consisted of four ‘high frequency” (15 Hz) trains i.e., rat received a total 
number 200 or 800 stimuli per day. The stimuli were delivered over 30 to 45 mins. The 
treatment dose used may also be relevant in humans, since higher rTMS intensities have 
been shown to have stronger antidepressive effects in patients (Padberg et al., 2002). 




Control rats were anesthetized the same way as treated ones, but pulses were delivered at 
a distance of more than 10 cm from the head (Ji et al., 1998). 
 Rats were sacrificed one week after the last day of rTMS or sham treatment, a 
time when therapeutic effects are expected in human patients receiving rTMS for 
depression (Pascual-Leone et al., 1996, Eschweiler et al., 2000). They were deeply 
anaesthetized, decapitated, and the left and right PFC, hippocampus and striatum were 
dissected out, snap frozen in liquid nitrogen, and kept in a -80 
o
C freezer until analyses. 
All procedures involving animals were approved by the Institutional Animal Care and 
Use Committee of the National University of Singapore, and in accordance with the 
guidelines of the National Advisory Committee for Laboratory Animal Research. 
 
3.3.2.2. Lipidomics analyses 
3.3.2.2.1. Lipid extraction 
Lipid extraction was carried out as previously described in 3.1.2.2.1.  
 
3.3.2.2.2. Internal standards 
 Internal standards used were as previously described in 3.2.2.6.2. 
 
3.3.2.2.3. Analyses of lipids using HPLC / mass spectrometry 
Analyses of lipids were carried out as previously described in 3.1.2.2.3. Based on 
product ion and precursor ion analyses of head groups, two comprehensive sets of MRM 




transitions were set up for quantitative analyses of various lipids including PCs, PEs, PSs, 
PIs, PGs, PAs, SMs, Cers and SLs (Fei et al., 2008).  
 
3.3.2.2.4. Statistical analyses 
 Comparisons of means were carried out using one-way ANOVA followed by 
Bonferroni’s post-hoc test. P < 0.05 was considered significant.  
 
3.3.2.3. Real-time RT-PCR 
An additional eight rats were used for this portion of the study. Four rats received 
800 rTMS stimuli at 100% intensity and four sham controls were used. The rats were 
sacrificed 1 week from the last day of rTMS treatment. Total RNA was extracted from 
the PFC using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s 
protocol and RNeasy® MiniKit (Qiagen, Inc., CA, USA) was used to purify the RNA. 
The samples were then reverse transcribed using the High-Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems, CA, USA). Reaction conditions were as follows: 
25 
o
C for 10 mins, 37 
o
C for 120 mins and 85 
o
C for 5 secs. Subsequently, real-time PCR 
amplification was carried out via the 7500 Realtime PCR system (Applied Biosystems, 
CA, USA) using TaqMan® Universal PCR MasterMix (Applied Biosystems, CA, USA) 
and probes which labeled the enzymes along in the SL biosynthetic or breakdown 
pathway, SPT, 3-dehydrosphinganine reductase (3KDAR), UDP-glycosyltransferase 8 
(UDP-8), GAL-3 and arylsulfatase-A (ARSA) respectively were utilized according to the 
manufacturers’ instructions. Beta-actin was used as an internal control and all primers 
and probes were synthesized by Applied Biosystems. The PCR conditions were: an initial 




incubation of 50 
o
C for 2 mins and 95 
o
C for 10 mins followed by 40 cycles of 95 
o
C for 
15 secs and 60 
o
C for 1 min. All reactions were carried out in triplicates. The threshold 
cycle, CT, which correlates inversely with the levels of target mRNA, was measured as 
the number of cycles at which the reporter fluorescence emission exceeds the preset 
threshold level. The amplified transcripts were quantified using the comparative CT 
method as described previously (Livak and Schmittgen, 2001) with the formula for 
relative fold change = 2
-∆∆CT
. The mean was calculated and possible significant 
differences between the PFC of rTMS-treated and control specimens were analyzed using 
the Student’s t-test. P < 0.05 was considered significant. Outliers identified by the Real-
time PCR system were also removed prior to statistical calculations.  
 
3.3.3. Results 
 Results from one-way ANOVA showed that brain regions (PFC / striatum) and 
doses of rTMS had a significant effect on the relative abundances of most lipids (F values 
not shown, P<0.05). However, relative abundance of brain lipids did not differ 
significantly between left and right brain regions (F values not shown, P>0.05). The 
following sections will further elaborate the differences in mean relative abundances 
amongst the various brain regions and treatment groups.  
 
3.3.3.1. Effects of rTMS on lipids in the ipsilateral (left) hemisphere 
3.3.3.1.1. Left PFC  
 All significant changes in lipids were only observed at the highest dose of rTMS, 
namely 800 rTMS stimuli at 100% intensity. PEs showed significant changes in relative 




abundances in the PFC. Increase in relative abundances were observed with PE34p:1, 
PE36p:2, PE36p:1, PE36:1 and PE38p:1 (Figure 3.18A), whilst decrease in relative 
abundance was observed with majority of the other PEs, especially those with longer 
chains (PE34:1, PE36p:4, PE36:4, PE38p:6, PE38:6, PE40p:6, PE40:6 and PE40:5) 
(Figure 3.18A and B). 
 
Figure 3.18 Relative abundances of PEs in the left PFC after varying doses of 
rTMS. Asterisks indicate significant differences using one-way ANOVA with 












































































 There were also increases in abundances of most of the lysoPEs as compared to 
controls after treatment with the highest dose of  rTMS, namely lysoPE16:0p, lysoPE16:0, 
lysoPE18:1p, lysoPE18:0p and lysoPE22:6 (Figure 3.19). 
 
Figure 3.19 Relative abundances of lysoPEs in the left PFC after varying doses of 
rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05).   
 
 General increases in relative abundances of PCs were detected after the highest 
dose of rTMS. PC34:0p, PC36:3p, PC36:2p, PC36:1p, PC36:0p, PC38:4p, PC38:3p, 
PC38:2p, PC40:4p, PC40:3p, PC40:2p and PC40:1p showed significant increases in 
relative abundance (Figure 3.20A and B). Some other PCs such as PC32:2, PC32:1 and 


































































Figure 3.20 Relative abundances of PCs in the left PFC after varying doses of 
rTMS.  Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05).  
 
 On the other hand, lysoPCs mainly increased in relative abundance after rTMS. 
The affected species were lysoPC18:1 and lysoPC20:4, which showed an increase after 
both low and high does of rTMS (Figure 3.21). LysoPC18:0 and lysoPC20:0 were 
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Figure 3.21 Relative abundances of lysoPCs in the left PFC after varying doses of 
rTMS.  Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05).  
 
 SLs showed large increases in relative abundances after the highest dose of rTMS 
treatment, with almost all species being statistically significant (SL d18:1/22:1, SL 
d18:1/22:0, SL d18:1/24:1, SL d18:1/24:0, SL d18:1/24:1h and SL d18:1/24:0h) (Figure 
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Figure 3.22 Relative abundances of SLs in the left PFC after varying doses of 
rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05). 
 
3.3.3.1.2. Left hippocampus 
 No significant changes in lipids were found in the left hippocampus (data not 
shown). 
 
3.3.3.1.3. Left striatum 
 Changes in lipid species in the striatum were, in general, either unchanged 
amongst the various treatment groups, or opposite to the trend detected in the PFC.  
Similarly, significant lipid changes were only observed at the highest dose of rTMS. 
Increases in relative abundance of PE38p:6 and PE40:6 were observed in the striatum 
after treatment with rTMS (Figure 3.23B), although these lipids were decreased in the 
























































Figure 3.23 Relative abundances of PEs in the left striatum after varying doses of 
rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05). 
 



































































Figure 3.24 Relative abundances of lysoPEs in the left striatum after varying doses 
of rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05). 
 
 
 PC36:0p, PC38:3p, PC38:2p, PC40:4p, PC40:2p and PC40:1p showed decreases 
in relative abundances after rTMS (Figure 3.25A and B). This was in contrast to the 
significant increases in relative abundances of the same lipid species seen in the PFC 
(Figure 3.20A and B). PC36:4, PC38:6, PC40:7 and PC40:6 showed significant increases 
after rTMS (Figure 3.25A), again opposite to the trend observed in the same lipid species 





























































Figure 3.25 Relative abundances of PCs in the left striatum after varying doses of 
rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05). 
 
 LysoPCs were decreased after rTMS. Significant results were seen in lysoPC16:0, 








































































Figure 3.26 Relative abundances of lysoPCs in the left striatum after varying doses 
of rTMS. Asterisks indicate significant differences using one-way ANOVA with 
Bonferroni’s post-hoc test. (*, P< 0.05). 
 
 The changes in relative abundances of SLs in the striatum were opposite to that in 
the PFC. SLs showed large decreases in relative abundance (more than 50% as compared 
to controls) with all species being involved, i.e. SL d18:1/18:1h, SL d18:1/20:0, SL 
d18:1/22:1, SL d18:1/22:0, SL d18:1/24:1, SL d18:1/24:0, SL d18:1/24:1h, and SL 







































Figure 3.27 Relative abundances of SLs in the left striatum after varying doses of rTMS. 
Asterisks indicate significant differences using one-way ANOVA with Bonferroni’s post-
hoc test. (*, P< 0.05). 
 
 
3.3.3.2. Effects of rTMS on lipids in the contralateral (right) hemisphere 
 As mentioned earlier, results from one-way ANOVA did not show a significant 
effect on the relative abundances of brain lipids between left and right brain regions (F 
values not shown, P>0.05). Shown below is a tabulated summary of the relative 
abundance of lipids in the right brain PFC / striatum. Since there was no effect on relative 
abundances between left and right regions, similar trends were observed in lipid changes 
in the right PFC (Table 3.5) as compared to its left counterpart (Figures 3.18-3.22), as 
























































Relative abundance ( x10
-3
) of selected lipids in the right brain regions 







Phosphatidylethanolamines     
PE34p:1 18.19±2.52 35.77±1.01* 56.00±2.83 46.47±4.06* 
PE34:1 12.81±0.47 11.66±0.50 10.79±1.00 10.47±0.96 
PE36p:4 36.72±3.68 31.45±3.37 35.97±6.27 44.20±3.17 
PE36p:2 22.89±3.92 55.53±1.90* 81.15±8.85 67.40±7.75 
PE36p:1 20.07±1.88 45.20±2.98* 67.23±8.99 60.09±1.11 
PE36:4 12.10±0.80 10.41±0.43 7.44±1.24 7.84±1.02 
PE36:1 16.54±0.71 21.35±1.42* 23.16±1.24 20.50±2.00 
PE38p:6 55.98±1.74 48.19±3.04* 47.92±2.99 65.66±1.13* 
PE38p:1 2.56±0.60 6.74±0.61* 10.62±1.38 11.07±0.90 
PE38:6 39.98±1.66 30.80±2.74* 19.74±1.92 19.61±1.20 
PE40p:6 106.68±6.13 89.00±2.10* 65.00±3.98 70.78±3.37 
PE40:6 154.35±3.07 120.25±2.16* 80.18±7.65 105.58±7.78* 
PE40:5 16.26±0.71 11.73±0.46* 8.32±1.24 9.67±1.82 
Lysophosphatidylethanolamines     
LysoPE16:0p 3.16±0.47 4.12±0.46 7.16±0.62 8.19±1.10 
LysoPE16:0 1.16±0.14 1.28±0.20 1.24±0.43 1.32±0.26 
LysoPE18:1p 4.21±0.53 10.74±0.63* 20.31±1.84 19.89±0.53 
LysoPE18:0p 7.36±0.53 11.03±0.82* 16.34±1.34 15.34±1.04 
LysoPE20:4 0.82±0.22 1.39±0.26 0.60±0.12 1.83±0.20* 
LysoPE22:6 0.44±0.12 0.86±0.15* 0.52±0.18 0.63±0.06 
Phosphatidylcholines     
PC32:2 5.69±0.33 3.75±0.39* 3.92±0.47 3.22±0.28 
PC32:1 38.21±1.69 31.92±2.02* 29.53±1.67 27.57±1.17 
PC34:0p 11.34±1.28 26.90±1.16* 41.00±7.98 34.19±1.57 
PC36:3p 1.31±0.14 2.33±0.13* 2.92±0.48 2.37±0.21 
PC36:2p 0.92±0.14 2.63±0.09* 3.79±0.69 2.95±0.29 
PC36:1p 2.35±0.37 7.05±0.22* 10.55±1.47 8.93±0.21 
PC36:0p 4.80±0.61 8.95±0.43* 12.14±1.84 10.58±0.52 
PC36:4 35.57±1.26 32.58±0.99 28.09±1.44 32.23±0.50* 
PC38:4p 0.78±0.06 1.20±0.10* 1.41±0.19 1.47±0.04 
PC38:3p 0.97±0.07 1.32±0.18 1.80±0.12 1.50±0.14 
PC38:2p 0.29±0.03 0.67±0.06* 1.70±0.20 1.02±0.06* 
PC38:6 24.77±2.00 24.25±0.97 20.63±0.76 23.09±0.71* 
PC40:4p 0.39±0.07 0.64±0.04* 0.86±0.07 0.67±0.05* 
PC40:3p 0.33±0.03 0.48±0.01* 0.65±0.12 0.54±0.02 
PC40:2p 0.13±0.02 0.29±0.02* 0.74±0.17 0.41±0.04 
PC40:1p 0.20±0.04 0.52±0.07* 1.13±0.13 0.72±0.08* 
PC40:7 4.59±0.31 4.52±0.14 4.89±0.45 6.13±0.54* 
PC40:6 15.94±0.83 15.91±0.22 15.51±1.34 18.80±0.49* 
Lysophosphatidylcholines     
LysoPC16:0 0.89±0.08 0.99±0.06 0.99±0.10 0.86±0.02 
LysoPC18:2 0.44±0.13 0.22±0.01 0.45±0.17 0.30±0.06 
LysoPC18:1 0.58±0.08 0.67±0.03 0.96±0.14 0.78±0.02 
LysoPC18:0 0.67±0.07 0.79±0.05 1.24±0.23 0.88±0.02 
LysoPC20:0 0.18±0.06 0.19±0.05 0.36±0.02 0.16±0.05* 
LysoPC20:4 0.14±0.03 0.13±0.01 0.15±0.06 0.16±0.03 
Sulfatides     
SL d18:1/18:1h 0.26±0.08 0.40±0.02 0.85±0.10 0.29±0.01* 
SL d18:1/20:0 2.28±0.31 2.38±0.22 3.69±0.44 1.31±0.18* 
SL d18:1/22:1 0.30±0.10 0.61±0.08* 1.43±0.33 0.49±0.07* 
SL d18:1/22:0 1.01±0.29 2.41±0.41* 5.34±1.47 1.68±0.16* 
SL d18:1/24:1 5.50±1.41 12.46±1.66* 28.63±6.81 9.02±0.66* 
SL d18:1/24:0 4.71±1.13 10.06±1.96* 20.74±5.03 6.83±0.63* 
SL d18:1/24:1h 1.66±0.42 3.13±0.48* 5.82±1.08 1.97±0.15* 
SL d18:1/24:0h 3.21±0.77 6.46±0.96* 10.53±2.55 3.53±0.43* 
 
Table 3.5 Changes in relative abundance of lipids in the right PFC / right 
striatum after the highest dose of rTMS treatment. All values are expressed as 
mean relative abundance ± SD. Results for low dose rTMS are not shown. 




Asterisk indicates significant differences using one-way ANOVA followed by 
Bonferroni's post hoc test. (*,  P<0.05) 
 
 
3.3.3.2.1. Right PFC 
Similar changes in relative abundance of lipid were observed in the right PFC as 
compared to the left PFC, except that there were fewer significant results. Shorter chains 
PEs (PE34p:1, PE36p:2, PE36p:1, PE36:1 and PE38p:1) showed significant increases in 
relative abundance, whilst decreases in relative abundance were observed in the longer 
chains PEs (PE38p:6, PE38:6, PE40p:6, PE40:6 and PE40:5) (Table 3.5). There was also 
an increase in abundance in lysoPEs as compared to controls after treatment with rTMS, 
namely lysoPE18:1p, lysoPE18:0p and lysoPE22:6 (Table 3.5). 
  Increases in PCs were generally detected after rTMS. PC34:0p, PC36:3p, 
PC36:2p, PC36:1p, PC36:0p, PC38:4p, PC38:2p, PC38:3, PC40:4p, PC40:3p, PC40:2p 
and PC40:1p showed significant increase after rTMS (Table 3.5). Some other PCs such 
as PC32:2 and PC32:1were significantly decreased. No significant changes were seen in 
lysoPCs (Table 3.5). 
 SLs showed large increases in relative abundance after rTMS treatment, with SL 
d18:1/22:1, SL d18:1/22:0, SL d18:1/24:1, SL d18:1/24:0, SL d18:1/24:1h and SL 
d18:1/24:0h showing significant increase (Table 3.5). Similar to the left PFC, the increase 
in relative abundance was more than 100% when compared to controls. 
 
3.3.3.2.2. Right hippocampus 
No significant changes in lipids were found in the right hippocampus. 
 




3.3.3.2.3. Right striatum 
 The right striatum showed a similar trend to the left striatum and opposite to that 
detected in the right PFC. Again, increase in relative abundance in PE38p:6 and PE40:6 
were observed in the right striatum after treatment with rTMS although these lipids 
showed a trend to a decrease in the right PFC (Table 3.5). LysoPE20:4 showed increase 
in relative abundance after rTMS (Table 3.5).  
 Few changes were seen in PCs and lysoPCs. PC38:2p, PC40:4p, PC40:1p and 
lysoPC20:0 showed significant decreases in relative abundance after rTMS (Table 3.5).  
 The changes in SLs in the right striatum were opposite to that in the right PFC. 
SLs showed a large decrease in relative abundance with all species being involved, i.e. 
SL d18:1/18:1h, SL d18:1/20:0, SL d18:1/22:1, SL d18:1/22:0, SL d18:1/24:1, SL 
d18:1/24:0, SL d18:1/24:1h, and SL d18:1/24:0h (Table 3.5). 
 
3.3.3.3. Real time RT-PCR analyses of enzymes involved in the SL biosynthetic 
pathway 
 No significant differences in mRNA expression of enzymes involved in SL 
biosynthetic or catabolic pathways were detected after rTMS. 





Figure 3.28 Real-time RT-PCR analyses of differentially expressed enzymes 
involved in SL biosynthetic pathway in the rat PFC after rTMS. Data were 





 The present study aimed to elucidate the effect of rTMS on global lipid profiles in 
different parts of the brain important in depression. Lipidomic analyses of different parts 
of the rat brain was carried out after 5 days of rTMS treatment followed by an interval of 
7 days, to mimic a treatment protocol that has been shown to be effective in the 
management of major depression in human patients, where a minimum course of 5 days 
rTMS was used, and effects expected after a week (Pascual-Leone et al., 1996, 
Eschweiler et al., 2000). Brain regions and treatment groups had a significant effect on 
the lipid profiles, whilst no effect on lipid profiles was observed between left and right 
sides of the same region analysed.  
 SLs showed large and significant increases in relative abundances after 800 
stimuli of rTMS at 100% intensity. The individual species involved were SL d18:1/22:1, 




SL d18:1/22:0, SL d18:1/24:1, SL d18:1/24:0, SL d18:1/24:1h, SL d18:1/24:0h. Increase 
in SL levels may be due to rTMS-mediated increase in ATP (Feng et al., 2008), which is 
necessary for synthesis of PAPS, a reactant required for the synthesis of SLs in brain 
tissues (Farooqui, 1981). SLs are important constituents of myelin for structural 
stabilization, and mediate diverse biological processes including the regulation of cell 
growth, protein trafficking, signal transduction, cell adhesion and neuronal plasticity 
(Ishizuka, 1997, Honke et al., 2004). Reduction in SLs is one of the earliest detectable 
lipid changes in the brain, and is thought to contribute to AD progression (Han et al., 
2002). SLs aid in the clearance of Aβ, and substantially lower amounts of SLs were 
found in human apoE4 transgenic mice as compared to wild type mice (Han et al., 2003). 
We postulate that increased SLs could underlie the improvement in cognitive 
performance after rTMS in patients with AD (Cotelli et al., 2006). We surveyed the 
mRNA expression of enzymes involved in synthesis or breakdown of SLs after rTMS 
using real-time RT-PCR, but did not detect significant changes. This suggests that the 
changes in SL after rTMS were not due to alterations in mRNA expression of SL 
biosynthetic or catabolic enzymes. 
 rTMS treatment also resulted in significant increase in many PEs and PCs in the 
left and right PFC. The species involved included PE34p:1, PE36p:2, PE36p:1, PE36:1, 
PE38p:1, lysoPE16:0p, lysoPE16:0, lysoPE18:1p, lysoPE18:0p, lysoPE22:6, PC34:0p, 
PC36:3p, PC36:2p, PC36:1p, PC36:0p, PC38:4p, PC38:3p, PC38:2p, PC40:4p, PC40:3p, 
PC40:2p and PC40:1p. The majority of the PCs and PEs exhibiting changes were of the 
plasmalogen class (E.g. 34p:1, the symbol “p” representing a vinyl ether linkage to the 




glycerol chain at the sn-1 position). Plasmalogens usually contain AA or DHA at the sn-2 
position.  
 In contrast to the increase in the PEs and PCs mentioned above, PEs with long 
chain PUFA chains (PE38p:6, PE38:6, PE40p:6 and PE40:6) showed significant decrease 
in relative abundance after high dose rTMS in the PFC. Based on the corresponding 
increase in lysophospholipid species, lysoPE16:0p, lysoPE16:0, lysoPE18:1p, 
lysoPE18:0p and lysoPE22:6, we can deduce the identity of the fatty acid side chain 
being released (Table 3.6). The results are consistent with increased activity of iPLA2 and 
PlsEtn-PLA2, which act on the sn-2 position of phospholipids to produce DHA 
Phospholipid Lysophospholipid 
released 
Fatty acid side chain being 
cleaved off via PLA2 activity 
PE38p:6 lysoPE16:0p 38p:6 – 16:0p = 22.6 (DHA) 
PE38:6 lysoPE16:0 38:6 – 16:0 = 22:6 (DHA) 
PE40p:6 lysoPE18:0p 40p:6 – 18:0p = 22.6 (DHA) 
  
 Table 3.6 Examples of possible phospholipid hydrolysis by PLA2 enzymes to 
release DHA and lysophospholipid. 
 
(Farooqui and Horrocks, 2001a). Long chain fatty acids such as DHA could be 
metabolized to resolvins and neuroprotectins that have neuroprotective and anti-
inflammatory effects (Bazan, 2009a, Farooqui, 2009b). The previous study has indicated 
possible involvement of intracellular PLA2s (probably iPLA2) and release of long chain 
fatty acids in the mouse PFC after chronic antidepressant treatment (Lee et al., 2009). It is 
possible that treatment modalities of depression may involve the induction of PLA2 
isoforms to release endogenous PUFAs, which have antidepressant effects (DeMar et al., 
2006, Rao et al., 2007b). 




 Interestingly, many of the lipid changes in the striatum were opposite to that of 
the PFC. PEs and PCs species that were increased in the PFC, were decreased in the 
striatum after rTMS. In particular, the level of SLs decreased in the left and right striatum 
after rTMS, as opposed to its large increases in the left and right PFC. The reason for the 
opposing changes in the striatum compared to the PFC is unknown, but it is possible that 
the PFC and striatum may be linked in an 'inverse' manner (Wilkinson, 1997). In addition, 
another explanation could be the large numbers of medium spiny γ-aminobutyric acid 
neurons in these nuclei. These neurons not only send projections to the globus pallidus 
externa or the globus pallidus interna / substantia nigra pars reticulata, but also recurrent 
projections to neighboring medium spiny neurons (Koos and Tepper, 1999). It is 
postulated that rTMS could result in net inhibition of the striatum due to stimulation of 
recurrent GABAergic collaterals of medium spiny neurons. In contrast, the treatment is 
expected to result in excitation of the PFC, in view of its predominant glutamatergic cell 
population (Celada et al., 2001).   
 Considering the size of the coil (7 cm), it is likely that the stimulation might have 
extended to brain areas beyond the PFC, which was the area of interest in this study. In 
studies carried out by other research groups, rTMS applied with a 7 cm coil reduced 
immobility time in FST and also effectively modulated beta-adrenergic and serotonergic 
receptor levels in the forebrain of rats (Ben-Shachar et al., 1999, Sachdev et al., 2002, 
Kim et al., 2006). These results suggest that data sets with large coils including this might 
still be compatible with those obtained by small coils. Still, the possibility that the 
changes in lipids observed might be due to alterations in other brain regions cannot be 
completely excluded. 




The rats were administered rTMS while anaesthetized to minimize restraint stress. Since 
there is a possibility that anaesthetics might affect brain lipid composition, the sham 
treated controls were anaesthetized similarly to ensure that any changes observed were 
due to the rTMS treatment. It is noted, however, that the results may not be exactly 
comparable in humans who are not anaesthetized during rTMS. The results of rTMS 
treatment were different from that observed after excitotoxicity induced by kainate 
injections (Guan et al., 2006). Kainate injections resulted in seizures, and decrease in 
phospholipids species with mainly polyunsaturated fatty acyl chains but increase in the 
Cers and lysophospholipid species, indicating increase in cPLA2 activity (Guan et al., 
2006). In contrast, seizures were not observed, and general increase, rather than decrease, 
in phospholipids was detected after rTMS. 
 In conclusion, the present study showed significant changes in rat brain lipids 
after rTMS. While recognizing that rat frontal cortex structure and connectivity to other 
brain areas differs from the human frontal cortex and the results may not be completely 
extrapolated to humans, it is hoped that these findings could provide some insights into 
possible changes in brain lipids that could contribute to the effects of rTMS in the 
management of neurological disorders. Further studies are necessary to elucidate possible 
changes in signaling pathways of SL, plasmalogens, and DHA metabolites after rTMS. 
























 Growing evidence have indicated an important role for lipids in neurological 
conditions such as stroke, AD, depression and many others (Adibhatla and Hatcher, 
2007). Glycerophospholipids and plasmalogens especially, serve as a reservoir for the 
generation of various lipid mediators, such as platelet activating factor and eicosanoids. 
Depression, in particular, has been associated with dietary levels of omega-3 PUFAs. 
Population studies have shown that frequent fish consumption containing substantial 
amounts of omega-3 PUFAs is associated with decreased risk of depression (Hibbeln, 
1998). Plasma and red blood cells concentrations of omega-3 fatty acids in depressed 
patients, especially DHA, have been unusually low, whilst the concentrations of AA have 
been relatively high (Peet et al., 1998, Maes et al., 1999). This imbalance of the omega-6 
/ omega-3 PUFA ratio in depression is accompanied by increased levels of formation of 
eicosanoids and production of proinflammatory cytokines, possibly with the involvement 
of PLA2 enzymes, and this would be detrimental to human brain function (Maes et al., 
1996, Hulbert et al., 2005). On the other hand, omega-3 PUFAs decrease production of 
these eicosanoids (Calder, 2001, Simopoulos, 2002).  
 Despite numerous studies carried out, an unknown research area still remains with 
regards to the exact lipid abberations taking place in depression or after antidepressant 
treatments. The first part of this study sets out to shed light on the lipid changes after 
chronic antidepressant treatment (maprotiline, fluoxetine and paroxetine). Lipidomics, 
which is a systems-level analyses and characterization of lipids and their interacting 
moieties, was carried out (Wenk, 2005, Adibhatla et al., 2006). Decreases in phospholipid 
species (PCs and PEs) was accompanied by increases in lysophospholipid species in the 




PFC after treatment with maprotiline and paroxetine. These changes suggested some 
form of PLA2 activity after antidepressant treatment, and based on the decreases and 
corresponding increases in lysophospholipid species, the identity of the fatty acid side 
chain being released was deduced (for instance, PC40:6 - lysoPC18:0 = 22:6 (DHA)). Of 
the three antidepressants tested, only fluoxetine did not exhibit any significant changes. 
This result is supported by recent preclinical findings which show no increase in omega-3 
PUFA biosynthesis or membrane composition after chronic fluoxetine treatment in rats 
(McNamara et al., 2010). In addition, no significant changes in lipid profiles were 
observed in the striatum, hippocampus and cerebellum in comparison to the PFC. This 
portion of the study showed that antidepressant treatments caused changes in 
phospholipid composition and possible endogenous release of long-chain PUFAs, 
including omega-3 fatty acids such as DHA. It is believed that the endogenous release of 
long-chain fatty acids may be related to the mechanism of action of the antidepressants.  
 Analyses of the relative expression of various PLA2 enzymes in the PFC of both 
control and maprotiline-treated mice found that iPLA2 was the most abundant enzyme in 
the PFC. The abundance of iPLA2 over other PLA2 enzymes was also observed in rats 
and monkey brains (Ong et al., 2005a, Ong et al., 2010). Besides, iPLA2 has a selective 
preference for DHA side chains in the sn-2 position of brain glycerophospholipids 
(Strokin et al., 2003, 2007, Green et al., 2008), thereby helping to regulate levels of free 
DHA. Omega-3 PUFAs levels affect signaling which in turn promote synaptic plasticity, 
neurogenesis, and adaptation associated with action of antidepressants (Warner-Schmidt 
and Duman, 2006). The above, coupled with the fact that abnormalities in activity of the 
PFC in depression have been reported more frequently than for any other brain region 




(Davidson et al., 2002), fuelled the second portion of the study looking specifically at the 
importance of  iPLA2 in the mechanism of maprotiline in the region of the PFC. 
In addition to lipidomics analyses, the modified FST (an animal model which is 
more sensitive in differentiating the mechanisms of action of antidepressants by detecting 
active behaviors displayed by the mice (Cryan et al., 2002), was used. The PFC was 
selected for i.c. injection of antisense oligonucleotide to iPLA2. FST results showed that 
administration of i.c. antisense oligonucleotide to i.p. maprotiline-treated mice 
significantly increased mean counts of immobility and decreased mean counts of 
climbing to levels comparable to saline-treated controls, indicating that it abolished the 
antidepressant effect of maprotiline. Lipidomic analyses further supported the behavioral 
data. Significant decreases in phospholipids and corresponding increases in 
lysophospholipids after i.p. maprotiline + saline / sense oligonucleotide treatment 
indicating PLA2 activity were observed. Again, based on the lipid changes, it is possible 
to deduce the identity of the fatty acid side chain being released (PC38p:6 – lysoPC16:0 
= 22:6 (DHA) and PE40p:7 – lysoPE 18:1 = 22:6 (DHA)). However, when i.c. antisense 
oligonucleotide to iPLA2 was administered along with i.p. maprotiline, the lipid changes 
were reversed and relative abundances became comparable to that of i.p. saline-treated 
controls. The abolishment of antidepressant activity of maprotiline with iPLA2 inhibition, 
and lack of release of long chain fatty acids, strongly suggest a role of iPLA2                                  
and DHA in the antidepressant effect of maprotiline.  
The last portion of the study looked at the lipid changes after rTMS, a treatment 
which has been recently been approved by the FDA for patients with drug refractory 
depression (Schutter, 2009). The aim was to observe if a different modality of 




antidepressant treatment would produce similar lipid changes. Lipidomic analyses of 
different parts of the rat brain was carried out after 5 days of rTMS treatment followed by 
an interval of 7 days, to mimic a treatment protocol that has been shown to be effective in 
the management of depression in human patients. Brain regions and treatment groups had 
a significant effect on the lipid profiles, whilst no effect on lipid profiles was observed 
between left and right sides of the same region analysed.  
Significant increases in many PEs and PCs in the left and right PFC were seen. In 
contrast to this increase, it was noticed that PEs with long chain PUFA showed 
significant decrease in relative abundance after high dose rTMS in the PFC. Based on the 
deduction of the identity of the fatty acid side chain being released, he results are 
consistent with increased activity of iPLA2 and PlsEtn-PLA2, which act on the sn-2 
position of phospholipids to produce DHA (e.g. PE38p:6 – LysoPE 16:0p = 22:6 (DHA); 
38:6 – 16:0 = 22:6 (DHA); 40p:6 – 18:0p = 22.6 (DHA)). A serendipitous discovery was 
seen in the class of lipids known as SLs. SLs showed large and significant increases in 
relative abundances after the highest dose of rTMS treatment. Reduction in levels of SLs 
is one of the earliest detectable lipid changes believed to be a contributing factor in the 
progression of AD (Han et al., 2002). Hence, increased SLs could underlie the 
improvement in cognitive performance after rTMS in patients with AD (Cotelli et al., 
2006).  
Collectively, the findings point to a change in lipid profiles after chronic 
antidepressant and rTMS treatments. Results were region-specific, involving mainly the 
PFC. Treatment modalities of depression may involve the induction of PLA2 isoforms to 




release endogenous PUFAs, which have antidepressant effects (DeMar et al., 2006, Rao 
et al., 2007b). An essential role for iPLA2 in the antidepressant effect of maprotiline has 
been established. Antisense oligonucleotide to iPLA2 rendered maprotiline an ineffective 
antidepressant as shown by FST results. Therefore, induction of iPLA2 after 
antidepressant treatment possibly releases PUFAs such as DHA. iPLA2 is important in 
synaptic plasticity and dietary PUFA deprivation in rats decreases the concentration of 
DHA in the frontal cortex and increases its half-life by decreasing the activity, protein 
and mRNA expression of iPLA2 in the rat frontal cortex (Rao et al., 2007a). It has been 
proposed that increased PLA2 activity may account for accelerated phospholipid turnover, 
excessive fusion of synaptic vesicles with presynaptic membranes, enhanced release of 
neurotransmitters as well as the alterations of some endogenous modulators of enzyme 
activity (Hibbeln, 1989), which may in turn affect mood control. In addition, studies have 
shown that DHA can be metabolized to resolvins and neuroprotectins that have 
neuroprotective and anti-inflammatory effects (Bazan, 2008). Of the protectins, NPD1 is 
able to suppress Aβ neurotoxicity in AD by inducing anti-apoptotic gene expression 
(Lukiw et al., 2005, Bazan, 2009b). Thus far however, it has not been investigated if 
either of the docosanoids generated have an anti-depressive role. 
In conclusion, antidepressant treatment modalities results in lipid changes, 
including decreases in particular phospholipids alongside increases in lysophospholipid 
species of the same lipid class, releasing FFAs such as DHA. iPLA2 plays an essential 
role in the antidepressant effect of maprotiline and possibly other antidepressants or 
antidepressant treatment modalities, via hydrolyzing the sn-2 bond of phospholipids to 
release DHA. Future studies to enhance the understanding of how antidepressants 




influence lipid composition could include investigating other commonly used 
antidepressants, looking at individual lipid species using in vitro experiments as well as 
varying the duration and dose of antidepressants used.
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